CAS 144689-63-4 | 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester | CAS Number 144689-63-4

Title	Journal
Impact of Olmesartan Medoxomil on Amiodarone-Induced Pulmonary Toxicity in Rats: Focus on Transforming Growth Factor-ß1.	Basic & clinical pharmacology & toxicology 20160701
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.	Toxicological sciences : an official journal of the Society of Toxicology 20131101
Anti-inflammatory and anti-oxidant activities of olmesartan medoxomil ameliorate experimental colitis in rats.	Toxicology and applied pharmacology 20130815
Pharmacokinetics of olmesartan medoxomil in pediatric patients with hypertension.	Paediatric drugs 20121201
Anti-atherogenic effects of the combination therapy with olmesartan and azelnidipine in diabetic apolipoprotein E-deficient mice.	The Tohoku journal of experimental medicine 20121201
Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.	The American journal of medicine 20121001
The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.	Diabetes & vascular disease research 20121001
Development and characterization of colloidal soft nano-carriers for transdermal delivery and bioavailability enhancement of an angiotensin II receptor blocker.	European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20121001
Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis.	American journal of cardiovascular drugs : drugs, devices, and other interventions 20121001
Efficacy of olmesartan medoxomil and hydrochlorothiazide fixed-dose combination therapy in patients aged 65 years and older with stage 1 and 2 hypertension or isolated systolic hypertension.	American journal of cardiovascular drugs : drugs, devices, and other interventions 20121001
Using different methods to evaluate the efficacy of olmesartan medoxomil in Chinese patients with mild to moderate essential hypertension according to ambulatory blood pressure monitoring.	Blood pressure monitoring 20121001
Electrochemical determination of olmesartan medoxomil using hydrothermally prepared nanoparticles composed SnO2-Co3O4 nanocubes in tablet dosage forms.	Talanta 20120915
Determination of eprosartan mesylate and hydrochlorothiazide in tablets by derivative spectrophotometric and high-performance liquid chromatographic methods.	Journal of chromatographic science 20120901
Stability-indicating method for simultaneous estimation of olmesartan medoxomile, amlodipine besylate and hydrochlorothiazide by RP-HPLC in tablet dosage form.	Journal of chromatographic science 20120901
High glucose potentiates and renin-angiotensin blockade downregulates LPS-induced tissue factor expression in human mononuclear cells.	Thrombosis research 20120901
Azilsartan medoxomil: a review of its use in hypertension.	Clinical drug investigation 20120901
Update on the ROADMAP clinical trial report: olmesartan for the prevention or delay of microalbuminuria development in type 2 diabetes.	Expert review of cardiovascular therapy 20120901
Angiotensin II-mediated up-regulation of connective tissue growth factor promotes atrial tissue fibrosis in the canine atrial fibrillation model.	Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 20120801
Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts.	Journal of cardiovascular pharmacology 20120801
Association study of genetic polymorphisms of drug transporters, SLCO1B1, SLCO1B3 and ABCC2, in African-Americans, Hispanics and Caucasians and olmesartan exposure.	Journal of human genetics 20120801
Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension.	Hypertension (Dallas, Tex. : 1979) 20120801
Severe spruelike enteropathy associated with olmesartan.	Mayo Clinic proceedings 20120801
Triple-Combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in black and non-black study participants with hypertension: the TRINITY randomized, double-blind, 12-week, parallel-group study.	American journal of cardiovascular drugs : drugs, devices, and other interventions 20120801
Nebivolol does not protect against 5/6 ablation/infarction induced chronic kidney disease in rats - comparison with angiotensin II receptor blockade.	Life sciences 20120726
Effects of angiotensin receptor blockers on endothelial nitric oxide release: the role of eNOS variants.	British journal of clinical pharmacology 20120701
Influence of ABCC2, SLCO1B1, and ABCG2 polymorphisms on the pharmacokinetics of olmesartan.	Journal of cardiovascular pharmacology 20120701
Enhanced intrarenal receptor-mediated prorenin activation in chronic progressive anti-thymocyte serum nephritis rats on high salt intake.	American journal of physiology. Renal physiology 20120701
Olmesartan medoxomil treatment potently improves cardiac myosin-induced dilated cardiomyopathy via the modulation of ACE-2 and ANG 1-7 mas receptor.	Free radical research 20120701
Short-term suppression of the renin-angiotensin system in mice associated with hypertension during pregnancy.	Molecular medicine reports 20120701
Twenty-four hour and early morning blood pressure control of olmesartan vs. ramipril in elderly hypertensive patients: pooled individual data analysis of two randomized, double-blind, parallel-group studies.	Journal of hypertension 20120701
Olmesartan for the prevention or delay of diabetic nephropathy: some considerations.	Revista espanola de cardiologia (English ed.) 20120701
Possible involvement of angiotensin-converting enzyme 2 and Mas activation in inhibitory effects of angiotensin II Type 1 receptor blockade on vascular remodeling.	Hypertension (Dallas, Tex. : 1979) 20120701
Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease.	International urology and nephrology 20120601
Predictors of proteinuria reduction by monotherapy with an angiotensin receptor blocker, olmesartan.	Journal of the renin-angiotensin-aldosterone system : JRAAS 20120601
Olmesartan medoxomil in children and adolescents with hypertension†: profile report.	Paediatric drugs 20120601
Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study.	Hypertension (Dallas, Tex. : 1979) 20120601
Calcium antagonist added to angiotensin receptor blocker: a recipe for reducing blood pressure variability?: evidence from day-by-day home blood pressure monitoring.	Hypertension (Dallas, Tex. : 1979) 20120601
Efficacy/safety of olmesartan medoxomil versus losartan potassium in naïve versus previously treated subjects with hypertension.	Advances in therapy 20120601
Combined effects of up- and downstream therapies on atrial fibrillation in a canine rapid stimulation model.	International journal of cardiology 20120531
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.	Journal of medicinal chemistry 20120524
Effective blockade of RAAS by combination of aliskiren and olmesartan improves glucose homeostasis, glomerular filtration rate along with renal variables in streptozotocin induced diabetic rats.	European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20120512
In situ intestinal permeability and in vivo absorption characteristics of olmesartan medoxomil in self-microemulsifying drug delivery system.	Drug development and industrial pharmacy 20120501
Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study.	Hypertension research : official journal of the Japanese Society of Hypertension 20120501
Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats.	American journal of hypertension 20120501
Management of blood pressure in children.	Current opinion in nephrology and hypertension 20120501
Heart angiotensin II-induced cardiomyocyte hypertrophy suppresses coronary angiogenesis and progresses diabetic cardiomyopathy.	American journal of physiology. Heart and circulatory physiology 20120501
Effect of nisoldipine and olmesartan on endothelium-dependent vasodilation in essential hypertensive patients.	CNS neuroscience & therapeutics 20120501
Blood pressure control with angiotensin receptor blocker-based three-drug combinations: key trials.	Advances in therapy 20120501
Efficacy/safety of olmesartan medoxomil versus losartan potassium in patients by stage 1 or 2 hypertension.	Postgraduate medicine 20120501
Reduction of the morning blood pressure surge treated with olmesartan in Chinese patients with mild to moderate essential hypertension--a multicenter, open-label, single treatment group clinical study.	European review for medical and pharmacological sciences 20120501
Olmesartan attenuates the development of heart failure after experimental autoimmune myocarditis in rats through the modulation of ANG 1-7 mas receptor.	Molecular and cellular endocrinology 20120404
Angiotensin II receptor blocker combinations: from guidelines to clinical practice.	Blood pressure 20120401
Increased mortality in patients with diabetes associated with olmesartan for the prevention/delay of microalbuminuria onset: a matter of concern?	Revista espanola de cardiologia (English ed.) 20120401
Revelation on the potency of α(1) -blockers - parallel blockade of angiotensin II receptor: a new finding.	Pharmaceutical biology 20120401
Effects of valsartan versus olmesartan addition to amlodipine/hydrochlorothiazide combination in treating stage 2 hypertensive patients.	Expert opinion on pharmacotherapy 20120401
Prevention of microalbuminuria in patients with type 2 diabetes and hypertension.	Journal of hypertension 20120401
Effect of an L- and T-type calcium channel blocker on 24-hour systolic blood pressure and heart rate in hypertensive patients.	Korean circulation journal 20120401
Angiotensin II receptor blocker partially ameliorated intrarenal hypoxia in chronic kidney disease patients: a pre-/post-study.	Internal medicine journal 20120401
[Hypertension: improved therapy adherence after switch to a fixed drug combinations].	MMW Fortschritte der Medizin 20120322
Renal sympathetic denervation suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation.	Circulation 20120320
Key advances in antihypertensive treatment.	Nature reviews. Cardiology 20120320
Activation of renal angiotensin type 1 receptor contributes to the pathogenesis of progressive renal injury in a rat model of chronic cardiorenal syndrome.	American journal of physiology. Renal physiology 20120315
Abilities of candesartan and other AT(1) receptor blockers to impair angiotensin II-induced AT(1) receptor activation after wash-out.	Journal of the renin-angiotensin-aldosterone system : JRAAS 20120301
Protective actions of nebivolol on chronic nitric oxide synthase inhibition-induced hypertension and chronic kidney disease in the rat: a comparison with angiotensin II receptor blockade.	Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20120301
Addition of aliskiren to olmesartan ameliorates tubular injury in chronic kidney disease patients partly by reducing proteinuria.	Journal of the renin-angiotensin-aldosterone system : JRAAS 20120301
Aldosterone does not contribute to renal p21 expression during the development of angiotensin II-induced hypertension in mice.	American journal of hypertension 20120301
Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension.	Journal of clinical hypertension (Greenwich, Conn.) 20120301
The role of ARBs alone or with HCTZ in the treatment of hypertension and prevention of cardiovascular and renal complications.	Postgraduate medicine 20120301
Modulation of renal superoxide dismutase by telmisartan therapy in C57BL/6-Ins2(Akita) diabetic mice.	Hypertension research : official journal of the Japanese Society of Hypertension 20120201
Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.	Drug metabolism and disposition: the biological fate of chemicals 20120201
Olmesartan medoxomil combined with hydrochlorothiazide improves 24-hour blood pressure control in moderate-to-severe hypertension.	Current medical research and opinion 20120201
Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial.	Circulation. Arrhythmia and electrophysiology 20120201
Development of safety profile evaluating pharmacokinetics, pharmacodynamics and toxicity of a combination of pioglitazone and olmesartan medoxomil in Wistar albino rats.	Regulatory toxicology and pharmacology : RTP 20120201
The use of modeling and simulation to guide clinical development of olmesartan medoxomil in pediatric subjects.	Clinical pharmacology and therapeutics 20120201
Direct angiotensin II type 2 receptor stimulation in Nω-nitro-L-arginine-methyl ester-induced hypertension: the effect on pulse wave velocity and aortic remodeling.	Hypertension (Dallas, Tex. : 1979) 20120201
Olmesartan/amlodipine: blood pressure lowering and beyond in special populations.	Therapeutic advances in cardiovascular disease 20120201
Effects of olmesartan and imidapril on the plasma adiponectin, P-selectin, and MDA-LDL levels of diabetic nephropathy patients.	Clinica chimica acta; international journal of clinical chemistry 20120118
Modulation of AT-1R/MAPK cascade by an olmesartan treatment attenuates diabetic nephropathy in streptozotocin-induced diabetic mice.	Molecular and cellular endocrinology 20120102
Losartan modulates muscular capillary density and reverses thiazide diuretic-exacerbated insulin resistance in fructose-fed rats.	Hypertension research : official journal of the Japanese Society of Hypertension 20120101
Olmesartan medoxomil treatment is associated with decreased plasma B-type natriuretic peptide levels in patients on hemodialysis.	Clinical and experimental hypertension (New York, N.Y. : 1993) 20120101
Olmesartan medoxomil and azelnidipine therapy in patients with hypertension and chronic kidney disease in Japan.	Journal of nephrology 20120101
Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study.	Journal of the American Society of Hypertension : JASH 20120101
Efficacy and tolerability of the single-pill combination of aliskiren 300 mg/amlodipine 10 mg in hypertensive patients not controlled by olmesartan 40 mg/amlodipine 10 mg.	Current medical research and opinion 20120101
Four-year clinical outcomes of the OLIVUS-Ex (impact of Olmesartan on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) extension trial.	Atherosclerosis 20120101
Endoplasmic reticulum stress and diabetic cardiomyopathy.	Experimental diabetes research 20120101
Olmesartan medoxomil is associated with decreased plasma AGEs, pentosidine, and N-(epsilon)-carboxymethyl-lysine levels in hemodialysis patients.	Clinical and experimental hypertension (New York, N.Y. : 1993) 20120101
Development of a novel 96-microwell assay with high throughput for determination of olmesartan medoxomil in its tablets.	Chemistry Central journal 20120101
Silicosis caused by chronic inhalation of snail shell powder.	Journal of Korean medical science 20120101
Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension.	Clinical and experimental hypertension (New York, N.Y. : 1993) 20120101
Cardio classics revisited: focus on the role of amlodipine.	Integrated blood pressure control 20120101
Involvement of PPAR-γ in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease.	Journal of neuroinflammation 20120101
How full is our antihypertensives pipeline?	Journal of pharmacology & pharmacotherapeutics 20120101
Secondary metabolites of Cynodon dactylon as an antagonist to angiotensin II type1 receptor: Novel in silico drug targeting approach for diabetic retinopathy.	Journal of pharmacology & pharmacotherapeutics 20120101
Solubilization of beclomethasone dipropionate in sterically stabilized phospholipid nanomicelles (SSMs): physicochemical and in vitro evaluations.	Drug design, development and therapy 20120101
Differential pharmacology and benefit/risk of azilsartan compared to other sartans.	Vascular health and risk management 20120101
Adoption of new drugs by physicians: a survival analysis.	BMC health services research 20120101
Therapeutic options for the treatment of hypertension in children and adolescents.	Clinical medicine insights. Circulatory, respiratory and pulmonary medicine 20120101
Olmesartan attenuates the impairment of endothelial cells induced by oxidized low density lipoprotein through downregulating expression of LOX-1.	International journal of molecular sciences 20120101
[Recent advance in kidney and hypertension research].	Nihon Jinzo Gakkai shi 20120101
Sex differences in primary hypertension.	Biology of sex differences 20120101
Proton and carbon ion radiotherapy for primary brain tumors delivered with active raster scanning at the Heidelberg Ion Therapy Center (HIT): early treatment results and study concepts.	Radiation oncology (London, England) 20120101
Major risk factors for the appearance of white-matter lesions on MRI in hypertensive patients with controlled blood pressure.	Vascular health and risk management 20120101
New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil.	Integrated blood pressure control 20120101
Combination therapy of olmesartan and azelnidipine inhibits sympathetic activity associated with reducing oxidative stress in the brain of hypertensive rats.	Clinical and experimental hypertension (New York, N.Y. : 1993) 20120101
Strategies to reverse endothelial progenitor cell dysfunction in diabetes.	Experimental diabetes research 20120101
The effect of antihypertensive drugs on endothelial function as assessed by flow-mediated vasodilation in hypertensive patients.	International journal of vascular medicine 20120101
What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment?	Cardiovascular diabetology 20120101
Emerging drug combinations to optimize renovascular protection and blood pressure goals.	International journal of nephrology and renovascular disease 20120101
Reciprocal interaction between macrophages and T cells stimulates IFN-γ and MCP-1 production in Ang II-induced cardiac inflammation and fibrosis.	PloS one 20120101
Different stability-indicating chromatographic techniques for the determination of netobimin.	Journal of analytical methods in chemistry 20120101
Comparison of the efficacy and safety of irbesartan and olmesartan in patients with hypertension (EARTH study).	Clinical and experimental hypertension (New York, N.Y. : 1993) 20120101
The role of apelin on the alleviative effect of Angiotensin receptor blocker in unilateral ureteral obstruction-induced renal fibrosis.	Nephron extra 20120101
Understanding the mechanism of hepatic fibrosis and potential therapeutic approaches.	Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association 20120101
Out-of-office blood pressure: from measurement to control.	Integrated blood pressure control 20120101
Critical evaluation of the efficacy and tolerability of azilsartan.	Vascular health and risk management 20120101
Angiotensin II, Aldosterone, and Anti-Inflammatory Lymphocytes: Interplay and Therapeutic Opportunities.	International journal of hypertension 20120101
Effects of olmesartan on arterial stiffness in rats with chronic renal failure.	Cardiovascular diabetology 20120101
Small molecules with similar structures exhibit agonist, neutral antagonist or inverse agonist activity toward angiotensin II type 1 receptor.	PloS one 20120101
Calcium channel blockers, more than diuretics, enhance vascular protective effects of angiotensin receptor blockers in salt-loaded hypertensive rats.	PloS one 20120101
Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic.	Vascular health and risk management 20120101
Effects of olmesartan, an angiotensin II receptor blocker, on peripheral insulin sensitivity in Japanese subjects with type 2 diabetes and hypertension.	Internal medicine (Tokyo, Japan) 20120101
Olmesartan improves coronary flow reserve of hypertensive patients using coronary magnetic resonance imaging compared with amlodipine.	Cardiology 20120101
Three in one: safety, efficacy, and patient acceptability of triple fixed-dose combination medicine in the management of hypertension.	Patient preference and adherence 20120101
Modulation of AT-1R/CHOP-JNK-Caspase12 pathway by olmesartan treatment attenuates ER stress-induced renal apoptosis in streptozotocin-induced diabetic mice.	European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20111218
Effect of olmesartan on oxidative stress in hypertensive patients: mechanistic support to clinical trials derived evidence.	Blood pressure 20111201
Thermal, dynamic and structural properties of drug AT1 antagonist olmesartan in lipid bilayers.	Biochimica et biophysica acta 20111201
Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study.	Diabetologia 20111201
Chronic angiotensin receptor blockade suppresses intracardiac angiotensin II in angiotensin II-infused rats.	Experimental biology and medicine (Maywood, N.J.) 20111201
Attenuation of hypertension-mediated glomerulosclerosis in conjunction with increased angiotensin (1-7).	Therapeutic advances in cardiovascular disease 20111201
Azilsartan medoxomil: a new angiotensin II receptor antagonist for treatment of hypertension.	The Annals of pharmacotherapy 20111201
24-hour efficacy and safety of Triple-Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: the TRINITY ambulatory blood pressure substudy.	Journal of clinical hypertension (Greenwich, Conn.) 20111201
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	PLoS computational biology 20111201
Prediction of drug combinations by integrating molecular and pharmacological data.	PLoS computational biology 20111201
Effect of Olmesartan on serum cystatin C levels in the patients with essential hypertension.	European review for medical and pharmacological sciences 20111201
[Series: Clinical study from Japan and its reflections; Olmesartan Reducing Incidence of Endstage Renal Disease in Diabetic Nephropathy Trial (ORIENT)].	Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20111110
Office and ambulatory pulse pressure--association with clinical characteristics and cardiovascular risk factors in normoalbuminuric patients with type 2 diabetes (ROADMAP study).	Journal of human hypertension 20111101
Effects of olmesartan on blood pressure and insulin resistance in hypertensive patients with sleep-disordered breathing.	Heart and vessels 20111101
Protective effects of L-type fatty acid-binding protein (L-FABP) in proximal tubular cells against glomerular injury in anti-GBM antibody-mediated glomerulonephritis.	Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20111101
The central mechanism underlying hypertension: a review of the roles of sodium ions, epithelial sodium channels, the renin-angiotensin-aldosterone system, oxidative stress and endogenous digitalis in the brain.	Hypertension research : official journal of the Japanese Society of Hypertension 20111101
Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.	European journal of pharmacology 20111101
Effects of 1-year administration of olmesartan on portal pressure and TGF-beta1 in selected patients with cirrhosis: a randomized controlled trial.	Journal of gastroenterology 20111101
Angiotensin receptor blockers shift the circadian rhythm of blood pressure by suppressing tubular sodium reabsorption.	American journal of physiology. Renal physiology 20111101
Role of angiotensin-converting enzyme 2 in cardiac hypertrophy induced by nitric oxide synthase inhibition.	Journal of hypertension 20111101
Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches.	European heart journal 20111101
Blood pressure outcomes in patients receiving angiotensin II receptor blockers in primary care: a comparative effectiveness analysis from electronic medical record data.	Journal of clinical hypertension (Greenwich, Conn.) 20111101
Azilsartan medoxomil: a new Angiotensin receptor blocker.	Clinical therapeutics 20111101
Single-pill triple-combination therapy: an alternative to multiple-drug treatment of hypertension.	Postgraduate medicine 20111101
A pilot study on the effect of telmisartan & ramipril on 24 h blood pressure profile & dipping pattern in type 1 diabetes patients with nephropathy.	The Indian journal of medical research 20111101
Alterations in adhesion junction precede gap junction remodelling during the development of heart failure in cardiomyopathic hamsters.	Cardiovascular research 20111001
The ROADMAP trial: olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.	Expert opinion on pharmacotherapy 20111001
Prepubertal angiotensin blockade exerts long-term therapeutic effect through sustained ATRAP activation in salt-sensitive hypertensive rats.	Journal of hypertension 20111001
The effect of amlodipine besylate, losartan potassium, olmesartan medoxomil, and other antihypertensives on central aortic blood pressure and biomarkers of vascular function.	Therapeutic advances in cardiovascular disease 20111001
Pharmacotherapy review of chronic pediatric hypertension.	Clinical therapeutics 20111001
Olmesartan, a novel angiotensin II type 1 receptor antagonist, reduces severity of atherosclerosis in apolipoprotein E deficient mice associated with reducing superoxide production.	Nutrition, metabolism, and cardiovascular diseases : NMCD 20110901
Effects of high dose olmesartan medoxomil plus hydrochlorothiazide on blood pressure control in patients with grade 2 and grade 3 hypertension.	Journal of human hypertension 20110901
Significance of pigment epithelium-derived factor levels with angiotensin II type 1 receptor blockers in patients with successful coronary stent implantation.	Journal of the renin-angiotensin-aldosterone system : JRAAS 20110901
Efficacy of Sevikar® compared to the combination of perindopril plus amlodipine on central arterial blood pressure in patients with moderate-to-severe hypertension: Rationale and design of the SEVITENSION study.	Contemporary clinical trials 20110901
Design, synthesis, bioconversion, and pharmacokinetics evaluation of new ester prodrugs of olmesartan.	European journal of medicinal chemistry 20110901
Long-term clinical and economic outcomes associated with angiotensin II receptor blocker use in hypertensive patients.	Current medical research and opinion 20110901
Seated cuff blood pressure-lowering efficacy of an olmesartan medoxomil-based treatment regimen in patients with type 2 diabetes mellitus.	Drugs in R&D 20110901
Severe angioedema associated with olmesartan.	Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20110901
Compliance, persistence, and switching patterns for ACE inhibitors and ARBs.	The American journal of managed care 20110901
[Case of olmesartan and amlodipine intoxication].	Chudoku kenkyu : Chudoku Kenkyukai jun kikanshi = The Japanese journal of toxicology 20110901
Design and rationale of Japanese evaluation between Formula of Azelnidipine and amlodipine add on olmesartan to Get antialbuminuric effect study (J-FLAG) : evaluation of the antialbuminuric effects between calcium channel blocker with sympatholytic action in hypertensive patients with diabetes and albuminuria.	Cardiovascular drugs and therapy 20110801
Sodium intake in men and potassium intake in women determine the prevalence of metabolic syndrome in Japanese hypertensive patients: OMEGA Study.	Hypertension research : official journal of the Japanese Society of Hypertension 20110801
Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.	Hypertension research : official journal of the Japanese Society of Hypertension 20110801
L-/T-type Ca channel blockers for kidney protection: ready for sophisticated use of Ca channel blockers.	Hypertension research : official journal of the Japanese Society of Hypertension 20110801
'ROADMAP' controversies.	Journal of clinical hypertension (Greenwich, Conn.) 20110801
Purification and identification of activating enzymes of CS-0777, a selective sphingosine 1-phosphate receptor 1 modulator, in erythrocytes.	The Journal of biological chemistry 20110715
Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients.	Heart and vessels 20110701
[Fixed drug combinations in hypertension: a budget impact analysis for the Spanish Health System on the marketing of a fixed combination of olmesartan/amlodipine].	Atencion primaria 20110701
Olmesartan ameliorates peripheral nerve dysfunction in Zucker diabetic fatty rats.	Journal of hypertension 20110701
Fixed-combination therapy to improve blood pressure control: experience with olmesartan-based therapy.	Expert review of cardiovascular therapy 20110701
The significance of the j-curve in hypertension and coronary artery diseases.	Korean circulation journal 20110701
Olmesartan, microalbuminuria, and type 2 diabetes.	The New England journal of medicine 20110609
Olmesartan, microalbuminuria, and type 2 diabetes.	The New England journal of medicine 20110609
Olmesartan, microalbuminuria, and type 2 diabetes.	The New England journal of medicine 20110609
Olmesartan, microalbuminuria, and type 2 diabetes.	The New England journal of medicine 20110609
Efficacy and safety of olmesartan medoxomil plus amlodipine in age, gender and hypertension severity defined subgroups of hypertensive patients.	Journal of human hypertension 20110601
Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study.	Journal of human hypertension 20110601
Olmesartan improves endothelial function in hypertensive patients: link with extracellular superoxide dismutase.	Hypertension research : official journal of the Japanese Society of Hypertension 20110601
Combining rosuvastatin with sartans of different peroxisome proliferator-activated receptor-γ activating capacity is not associated with different changes in low-density lipoprotein subfractions and plasma lipoprotein-associated phospholipase A₂.	Metabolic syndrome and related disorders 20110601
Role of intrarenal angiotensin system activation, oxidative stress, inflammation, and impaired nuclear factor-erythroid-2-related factor 2 activity in the progression of focal glomerulosclerosis.	The Journal of pharmacology and experimental therapeutics 20110601
The 'pyrrhic victory' of amlodipine over hydrochlorothiazide in the OLAS Study.	Journal of human hypertension 20110601
Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments.	Drug metabolism and disposition: the biological fate of chemicals 20110601
Changes in renal vessels following the long-term administration of an angiotensin II receptor blocker in Zucker fatty rats.	Journal of the renin-angiotensin-aldosterone system : JRAAS 20110601
The effect of antihypertensive agents in people at high risk of cardiovascular disease and diabetes: a view through smoke and mirrors.	Journal of human hypertension 20110601
Telmisartan exerts antiatherosclerotic effects by activating peroxisome proliferator-activated receptor-γ in macrophages.	Arteriosclerosis, thrombosis, and vascular biology 20110601
Mineralocorticoid receptor activation: a major contributor to salt-induced renal injury and hypertension in young rats.	American journal of physiology. Renal physiology 20110601
Pharmacotherapy: Olmesartan for microalbuminuria--friend or foe?	Nature reviews. Endocrinology 20110601
Estrogen-independent activation of estrogen receptors.	Hypertension (Dallas, Tex. : 1979) 20110601
Activation of estrogen receptor-α and of angiotensin-converting enzyme 2 suppresses ischemic brain damage in oophorectomized rats.	Hypertension (Dallas, Tex. : 1979) 20110601
Blood pressure-lowering efficacy of an olmesartan medoxomil/hydrochlorothiazide-based treatment algorithm in elderly patients (age ≥65 years) stratified by age, sex and race: subgroup analysis of a 12-week, open-label, single-arm, dose-titration study.	Drugs & aging 20110601
A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide.	Journal of clinical hypertension (Greenwich, Conn.) 20110601
Efficacy of amlodipine and olmesartan medoxomil in hypertensive patients with diabetes and obesity.	Journal of clinical hypertension (Greenwich, Conn.) 20110601
Epigallocatechin-3-gallate Regulates Inducible Nitric Oxide Synthase Expression in Human Umbilical Vein Endothelial Cells.	Laboratory animal research 20110601
Diabetes: ROADMAP: the road to renoprotection?	Nature reviews. Nephrology 20110524
Olmesartan severely weakened the development of NASH in an animal model of hypercholesterolemia.	Atherosclerosis 20110501
A pooled analysis of 20 post-authorization surveys of olmesartan involving 156,682 hypertensive patients.	Expert opinion on drug safety 20110501
Diabetes: olmesartan slows microalbuminuria.	Nature reviews. Cardiology 20110501
Long-term effects of Irbesartan treatment and smoking on nucleic acid oxidation in patients with type 2 diabetes and microalbuminuria: an Irbesartan in patients with type 2 diabetes and Microalbuminuria (IRMA 2) substudy.	Diabetes care 20110501
Angiotensin type 1 receptor blocker reduces intimal neovascularization and plaque growth in apolipoprotein E-deficient mice.	Hypertension (Dallas, Tex. : 1979) 20110501
Management of hypertension in patients with diabetes using an amlodipine-, olmesartan medoxomil-, and hydrochlorothiazide-based titration regimen.	The American journal of cardiology 20110501
Randomized Olmesartan And Diabetes Microalbuminuria Prevention Study (ROADMAP).	Polskie Archiwum Medycyny Wewnetrznej 20110501
The combination of amlodipine and angiotensin receptor blocker or diuretics in high-risk hypertensive patients: rationale, design and baseline characteristics.	Journal of human hypertension 20110401
Circadian rhythms in blood pressure regulation and optimization of hypertension treatment with ACE inhibitor and ARB medications.	American journal of hypertension 20110401
Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension.	Blood pressure. Supplement 20110401
Angiotensin II type 1 receptor blocker inhibits arterial calcification in a pre-clinical model.	Cardiovascular research 20110401
Telmisartan inhibits vasoconstriction via PPARγ-dependent expression and activation of endothelial nitric oxide synthase.	Cardiovascular research 20110401
Urinary albumin excretion during angiotensin II receptor blockade: comparison of combination treatment with a diuretic or a calcium-channel blocker.	American journal of hypertension 20110401
The role of ambulatory blood pressure monitoring compared with clinic and home blood pressure measures in evaluating moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy.	Blood pressure monitoring 20110401
Reduction of albuminuria with antihypertensive treatment: is more always better?	American journal of hypertension 20110401
Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: considerations on drug-drug interactions.	Biopharmaceutics & drug disposition 20110401
[Fixed dose combination of an ARB calcium antagonist lowers blood pressure effectively and improves quality of life].	MMW Fortschritte der Medizin 20110331
Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.	The New England journal of medicine 20110310
Preemptive olmesartan for the delay or prevention of microalbuminuria in diabetes.	The New England journal of medicine 20110310
Update on potential medical treatments for encapsulating peritoneal sclerosis; human and experimental data.	International urology and nephrology 20110301
In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies.	The Journal of pharmacology and experimental therapeutics 20110301
Comparison of combination therapies, including the angiotensin receptor blocker olmesartan and either a calcium channel blocker or a thiazide diuretic, in elderly patients with hypertension.	Hypertension research : official journal of the Japanese Society of Hypertension 20110301
Blockade of AT1 receptors protects the blood-brain barrier and improves cognition in Dahl salt-sensitive hypertensive rats.	American journal of hypertension 20110301
Association between aldosterone induced by antihypertensive medication and arterial stiffness reduction: the J-CORE study.	Atherosclerosis 20110301
Safety and efficacy of olmesartan: an observational pooled-analysis of 156,682 hypertensive patients.	Expert opinion on drug safety 20110301
Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.	Hypertension (Dallas, Tex. : 1979) 20110301
Triple-drug, fixed-dose combinations for the treatment of hypertension: focus on olmesartan/amlodipine/hydrochlorothiazide combination.	Drugs of today (Barcelona, Spain : 1998) 20110301
The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure.	Journal of clinical hypertension (Greenwich, Conn.) 20110201
Effects of angiotensin II receptor antagonist olmesartan on renal hemodynamic variables and vascular structural properties in streptozotocin-induced diabetic rats.	Chinese medical journal 20110201
Olmesartan medoxomil/amlodipine/hydrochlorothiazide: fixed-dose combination in hypertension.	Drugs 20110122
Co-treatment with azelinidipine and olmesartan inhibits advanced glycation end products (AGEs) elicited down-regulation of adiponectin mRNA levels in cultured adipocytes partly via its anti-oxidative property.	International journal of cardiology 20110121
Possible involvement of intracellular angiotensin II receptor in high-glucose-induced damage in renal proximal tubular cells.	Journal of nephrology 20110101
Possible Link between Metabolic Syndrome and Chronic Kidney Disease in the Development of Cardiovascular Disease.	Cardiology research and practice 20110101
Efficacy of olmesartan therapy on fibrinolytic capacity in patients with hypertension.	Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20110101
Comparative analysis of telmisartan and olmesartan on cardiac function in the transgenic (mRen2)27 rat.	American journal of physiology. Heart and circulatory physiology 20110101
Compliance, persistence, healthcare resource use, and treatment costs associated with aliskiren plus ARB versus ACE inhibitor plus ARB combination therapy: in US patients with hypertension.	American journal of cardiovascular drugs : drugs, devices, and other interventions 20110101
Olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide triple combination for hypertension.	Expert review of cardiovascular therapy 20110101
Effects of olmesartan medoxomil, an angiotensin II type 1 receptor antagonist, on plasma concentration of B-type natriuretic peptide, in hypertensive patients with type 2 diabetes mellitus: a preliminary, observational, open-label study.	Clinical drug investigation 20110101
Rodent models for metabolic syndrome research.	Journal of biomedicine & biotechnology 20110101
The development and the use of experimental animal models to study the underlying mechanisms of CA formation.	Journal of biomedicine & biotechnology 20110101
Angiotensin II receptor blocker induced fetopathy: 7 cases.	Klinische Padiatrie 20110101
Comparison of combination therapy of olmesartan plus azelnidipine or hydrochlorothiazide on renal and vascular damage in SHR/NDmcr-cp rats.	Kidney & blood pressure research 20110101
Chronopharmacology of angiotensin II-receptor blockers in stroke-prone spontaneously hypertensive rats.	Journal of pharmacological sciences 20110101
A randomized, double-blind, forced-titration study to compare olmesartan medoxomil versus losartan potassium in patients with stage 1 and 2 hypertension.	Postgraduate medicine 20110101
Central angiotensin II stimulation promotes β amyloid production in Sprague Dawley rats.	PloS one 20110101
Olmesartan, an AT1 antagonist, attenuates oxidative stress, endoplasmic reticulum stress and cardiac inflammatory mediators in rats with heart failure induced by experimental autoimmune myocarditis.	International journal of biological sciences 20110101
Use of Angiotensin receptor blockers in cardiovascular protection: current evidence and future directions.	P & T : a peer-reviewed journal for formulary management 20110101
Activation of Src mediates PDGF-induced Smad1 phosphorylation and contributes to the progression of glomerulosclerosis in glomerulonephritis.	PloS one 20110101
Hypertensive nephropathy treatment by heart-protecting musk pill: a study of anti-inflammatory therapy for target organ damage of hypertension.	International journal of general medicine 20110101
Moderate versus intensive treatment of hypertension using amlodipine/valsartan and with the addition of hydrochlorothiazide for patients uncontrolled on angiotensin receptor blocker monotherapy: results in racial/ethnic subgroups.	Journal of the American Society of Hypertension : JASH 20110101
HIV-1 accessory protein Vpr: relevance in the pathogenesis of HIV and potential for therapeutic intervention.	Retrovirology 20110101
Olmesartan medoxomil for the treatment of hypertension in children and adolescents.	Vascular health and risk management 20110101
Olmesartan/amlodipine: a review of its use in the management of hypertension.	Vascular health and risk management 20110101
Clinical utility of valsartan in the treatment of hypertension in children and adolescents.	Patient preference and adherence 20110101
Cardiovascular and Renal Links along the Cardiorenal Continuum.	International journal of nephrology 20110101
Adverse effect profile of trichlormethiazide: a retrospective observational study.	Cardiovascular diabetology 20110101
Combination delapril/manidipine as antihypertensive therapy in high-risk patients.	Clinical drug investigation 20110101
Novel ocular antihypertensive compounds in clinical trials.	Clinical ophthalmology (Auckland, N.Z.) 20110101
Reappraisal of role of angiotensin receptor blockers in cardiovascular protection.	Vascular health and risk management 20110101
A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors.	Vascular health and risk management 20110101
Mesenteric panniculitis presenting with acute non-occlusive colonic ischemia.	International archives of medicine 20110101
Choice of angiotensin receptor blocker in moderate hypertension. A UK-based cost-benefit comparison of olmesartan- and candesartan-based regimens.	Journal of medical economics 20110101
Olmesartan induces renoprotective effects by stimulating angiotensin type 2 receptors and reducing oxidative stress in diabetic nephropathy.	Kidney & blood pressure research 20110101
Differential Effects in Cardiovascular Markers between High-Dose Angiotensin II Receptor Blocker Monotherapy and Combination Therapy of ARB with Calcium Channel Blocker in Hypertension (DEAR Trial).	International journal of hypertension 20110101
Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study.	Vascular health and risk management 20110101
Cardiovascular outcomes with angiotensin II receptor blockers: clinical implications of recent trials.	Vascular health and risk management 20110101
Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil.	Vascular health and risk management 20110101
Animal models of calcific aortic valve disease.	International journal of inflammation 20110101
Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: a retrospective observational study.	Cardiovascular diabetology 20110101
Effects of olmesartan on the renin-angiotensin-aldosterone system for patients with essential hypertension after cardiac surgery--investigation using a candesartan change-over study.	Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia 20110101
Prevention and intervention studies with telmisartan, ramipril and their combination in different rat stroke models.	PloS one 20110101
Cardioprotective effects of telmisartan against heart failure in rats induced by experimental autoimmune myocarditis through the modulation of angiotensin-converting enzyme-2/angiotensin 1-7/mas receptor axis.	International journal of biological sciences 20110101
A critical appraisal of the clinical effectiveness of a fixed combination of valsartan, amlodipine, and hydrochlorothiazide in achieving blood pressure goals.	Integrated blood pressure control 20110101
Long-term use and tolerability of irbesartan for control of hypertension.	Integrated blood pressure control 20110101
Clinical utility of fixed-combination telmisartan-amlodipine in the treatment of hypertension.	Integrated blood pressure control 20110101
Development and characterization of nanosuspensions of olmesartan medoxomil for bioavailability enhancement.	Journal of pharmacy & bioallied sciences 20110101
Azilsartan: a newly approved angiotensin II receptor blocker.	Cardiology in review 20110101
Proteomic and biochemical analyses reveal the activation of unfolded protein response, ERK-1/2 and ribosomal protein S6 signaling in experimental autoimmune myocarditis rat model.	BMC genomics 20110101
Inverse agonism and its therapeutic significance.	Indian journal of pharmacology 20110101
Efficacy of fixed-dose amlodipine and losartan combination compared with amlodipine monotherapy in stage 2 hypertension: a randomized, double blind, multicenter study.	BMC research notes 20110101
Azelnidipine prevents cardiac dysfunction in streptozotocin-diabetic rats by reducing intracellular calcium accumulation, oxidative stress and apoptosis.	Cardiovascular diabetology 20110101
Hepatic mitochondrial dysfunction in Friedreich ataxia.	BMC neurology 20110101
Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk.	Vascular health and risk management 20110101
Lipid chaperones and metabolic inflammation.	International journal of inflammation 20110101
Peroxisome proliferator-activated receptor-gamma agonists suppress tissue factor overexpression in rat balloon injury model with paclitaxel infusion.	PloS one 20110101
Apelin and pulmonary hypertension.	Pulmonary circulation 20110101
[Multicenter trial of olmesartan. Main results].	Terapevticheskii arkhiv 20110101
Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ.	Vascular health and risk management 20110101
Changes in human fecal microbiota due to chemotherapy analyzed by TaqMan-PCR, 454 sequencing and PCR-DGGE fingerprinting.	PloS one 20110101
Differential clinical profile of candesartan compared to other angiotensin receptor blockers.	Vascular health and risk management 20110101
Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination.	Integrated blood pressure control 20110101
A pilot study to clinically evaluate the role of herbomineral compound 'Rakatchap Har' in the management of essential hypertension.	Ayu 20110101
Olmesartan medoxomil: in children and adolescents with hypertension.	Drugs 20101224
Long-term efficacy of a combination of amlodipine and olmesartan medoxomil ± hydrochlorothiazide in patients with hypertension stratified by age, race and diabetes status: a substudy of the COACH trial.	Journal of human hypertension 20101201
Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model.	Kidney international 20101201
Aliskiren, a renin inhibitor, downregulates TNF-α-induced tissue factor expression in HUVECS.	Journal of the renin-angiotensin-aldosterone system : JRAAS 20101201
Improving quality of life in hypertension management using a fixed-dose combination of olmesartan and amlodipine in primary care.	Expert opinion on pharmacotherapy 20101201
Comparison of angiotensin II type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice.	Hypertension research : official journal of the Japanese Society of Hypertension 20101201
Connective tissue growth factor induction in a pressure-overloaded heart ameliorated by the angiotensin II type 1 receptor blocker olmesartan.	Hypertension research : official journal of the Japanese Society of Hypertension 20101201
Development and validation of an LC-ESI-MS/MS method for simultaneous quantitation of olmesartan and pioglitazone in rat plasma and its pharmacokinetic application.	Biomedical chromatography : BMC 20101201
Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension.	Journal of human hypertension 20101101
The Renin-Angiotensin system mediates the effects of stretch on conduction velocity, connexin43 expression, and redistribution in intact ventricle.	Journal of cardiovascular electrophysiology 20101101
Coronary vascular dysfunction promoted by oxidative-nitrative stress in SHRSP.Z-Lepr(fa) /IzmDmcr rats with metabolic syndrome.	Clinical and experimental pharmacology & physiology 20101101
The counterregulating role of ACE2 and ACE2-mediated angiotensin 1-7 signaling against angiotensin II stimulation in vascular cells.	Hypertension research : official journal of the Japanese Society of Hypertension 20101101
Strong suppression of the renin-angiotensin system has a renal-protective effect in hypertensive patients: high-dose ARB with ACE inhibitor (Hawaii) study.	Hypertension research : official journal of the Japanese Society of Hypertension 20101101
Regression of superficial glomerular podocyte injury in type 2 diabetic rats with overt albuminuria: effect of angiotensin II blockade.	Journal of hypertension 20101101
Intrarenal suppression of angiotensin II type 1 receptor binding molecule in angiotensin II-infused mice.	American journal of physiology. Renal physiology 20101101
Beneficial effects of angiotensin II receptor blocker, olmesartan, in limiting the cardiotoxic effect of daunorubicin in rats.	Free radical research 20101101
Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study.	Journal of hypertension 20101101
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.	Bioorganic & medicinal chemistry letters 20101101
Beneficial effects of olmesartan, an angiotensin II receptor type 1 antagonist, in rats with dilated cardiomyopathy.	Experimental biology and medicine (Maywood, N.J.) 20101101
Spontaneous development of left ventricular hypertrophy and diastolic dysfunction in mice lacking all nitric oxide synthases.	Circulation journal : official journal of the Japanese Circulation Society 20101101
Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine.	British journal of cancer 20101101
Efficacy and safety of olmesartan medoxomil in patients with stage 1 hypertension: blood pressure lowering and goal achievement.	Postgraduate medicine 20101101
Metabolic regulation of coronary vascular tone: role of hydrogen peroxide, purinergic components, and angiotensin.	European journal of pharmacology 20101025
An angiotensin II type 1 receptor blocker can preserve endothelial function and attenuate brain ischemic damage in spontaneously hypertensive rats.	Journal of neuroscience research 20101001
A sensitive short-term evaluation of antifibrotic effects using newly established type I collagen reporter transgenic rats.	American journal of physiology. Renal physiology 20101001
Novel amides and esters prodrugs of olmesartan: Synthesis, bioconversion, and pharmacokinetic evaluation.	Bioorganic & medicinal chemistry letters 20101001
Efficacy of an olmesartan medoxomil-based treatment algorithm in patients with hypertension and type 2 diabetes: analysis of diurnal blood pressure control as assessed by 24-hour ambulatory blood pressure monitoring.	Therapeutic advances in cardiovascular disease 20101001
Efficacy and tolerability of olmesartan/amlodipine combination therapy in patients with mild-to-severe hypertension: focus on 24-h blood pressure control.	Therapeutic advances in cardiovascular disease 20101001
Tribenzor for hypertension.	The Medical letter on drugs and therapeutics 20100906
Chart review of patients on valsartan-based single-pill combinations vs. ARB-based free combinations for BP goal achievement.	Current medical research and opinion 20100901
Combination therapy for hypertension: focus on high-dose olmesartan medoxomil (40 mg) plus hydrochlorothiazide.	Expert opinion on pharmacotherapy 20100901
Effects of olmesartan vs irbesartan on metabolic parameters and visfatin in hypertensive obese women.	European review for medical and pharmacological sciences 20100901
Gateways to clinical trials.	Methods and findings in experimental and clinical pharmacology 20100901
Porphyria cutanea tarda induced by olmesartan.	Journal of the European Academy of Dermatology and Venereology : JEADV 20100801
Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients.	Hypertension research : official journal of the Japanese Society of Hypertension 20100801
Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study.	Therapeutic advances in cardiovascular disease 20100801
Pharmacological therapy for hypertensive children: an 'additional bypass' of lifestyle interventions.	Hypertension (Dallas, Tex. : 1979) 20100801
Protective effects of angiotensin II type-1 receptor blockade with olmesartan on spinal cord ischemia-reperfusion injury: an experimental study on rats.	Annals of vascular surgery 20100801
Stability indicating LC method for the simultaneous determination of amlodipine and olmesartan in dosage form.	Journal of chromatographic science 20100801
Inhibitory effects of olmesartan on catecholamine secretion from the perfused rat adrenal medulla.	The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 20100801
The relative bioavailability and fasting pharmacokinetics of three formulations of olmesartan medoxomil 20-mg capsules and tablets in healthy Chinese male volunteers: An open-label, randomized-sequence, single-dose, three-way crossover study.	Clinical therapeutics 20100801
Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study.	Clinical therapeutics 20100701
Blockade of renin-angiotensin system attenuates advanced glycation end products-mediated signaling pathways.	Journal of atherosclerosis and thrombosis 20100630
Angiotensin II type 1 receptor blockers prevent tumor necrosis factor-alpha-mediated endothelial nitric oxide synthase reduction and superoxide production in human umbilical vein endothelial cells.	European journal of pharmacology 20100625
AT1 blockade attenuates atherosclerotic plaque destabilization accompanied by the suppression of cathepsin S activity in apoE-deficient mice.	Atherosclerosis 20100601
Economic evaluation of four angiotensin II receptor blockers in the treatment of hypertension.	Current medical research and opinion 20100601
Development and validation of a discriminating in vitro dissolution method for a poorly soluble drug, olmesartan medoxomil: comparison between commercial tablets.	AAPS PharmSciTech 20100601
A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension.	Hypertension (Dallas, Tex. : 1979) 20100601
Beating the clock: reducing cardiovascular risk by rapid blood pressure reduction with olmesartan.	Expert opinion on pharmacotherapy 20100601
Prevention of microalbuminuria in patients with type 2 diabetes: what do we know?	Journal of clinical hypertension (Greenwich, Conn.) 20100601
Gateways to clinical trials.	Methods and findings in experimental and clinical pharmacology 20100601
Cardiac-specific activation of angiotensin II type 1 receptor-associated protein completely suppresses cardiac hypertrophy in chronic angiotensin II-infused mice.	Hypertension (Dallas, Tex. : 1979) 20100501
The angiotensin II type 1 receptor antagonist olmesartan preserves cerebral blood flow and cerebrovascular reserve capacity, and accelerates rehabilitative outcomes in hypertensive patients with a history of stroke.	The International journal of neuroscience 20100501
Olmesartan, an angiotensin II receptor blocker, restores cerebral hypoperfusion in elderly patients with hypertension.	Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 20100501
Gateways to clinical trials.	Methods and findings in experimental and clinical pharmacology 20100501
Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.	Clinical therapeutics 20100501
Human carboxymethylenebutenolidase as a bioactivating hydrolase of olmesartan medoxomil in liver and intestine.	The Journal of biological chemistry 20100416
ANG II receptor blockade enhances anti-inflammatory macrophages in anti-glomerular basement membrane glomerulonephritis.	American journal of physiology. Renal physiology 20100401
Combination therapy with olmesartan and azelnidipine improves EDHF-mediated responses in diabetic apolipoprotein E-deficient mice.	Circulation journal : official journal of the Japanese Circulation Society 20100401
Loss of ACE2 accelerates time-dependent glomerular and tubulointerstitial damage in streptozotocin-induced diabetic mice.	Hypertension research : official journal of the Japanese Society of Hypertension 20100401
Gateways to clinical trials.	Methods and findings in experimental and clinical pharmacology 20100401
Effect of olmesartan and pravastatin on experimental cerebral aneurysms in rats.	Brain research 20100331
Simultaneous quantitative determination of olmesartan and hydrochlorothiazide in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry.	Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100315
Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial.	Journal of the American College of Cardiology 20100309
Plaque burden with composition? That is the next question.	Journal of the American College of Cardiology 20100309
Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension--results from the EUTOPIA trial.	Atherosclerosis 20100301
Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes.	Current medical research and opinion 20100301
Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans.	Journal of hypertension 20100301
Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters.	Biopharmaceutics & drug disposition 20100301
RP-HPLC-DAD method for determination of olmesartan medoxomil in bulk and tablets exposed to forced conditions.	Acta pharmaceutica (Zagreb, Croatia) 20100301
Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.	Clinical therapeutics 20100301
Gateways to clinical trials.	Methods and findings in experimental and clinical pharmacology 20100301
Efficacy of olmesartan and nifedipine on recurrent hypoxia-induced left ventricular remodeling in diabetic mice.	Life sciences 20100227
Angiotensin II receptor blocker attenuates PDGF-induced mesangial cell migration in a receptor-independent manner.	Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20100201
Effects of walnut consumption on endothelial function in type 2 diabetic subjects: a randomized controlled crossover trial.	Diabetes care 20100201
Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension.	Hypertension research : official journal of the Japanese Society of Hypertension 20100201
Evaluation of blockbuster drugs under the rule-of-five.	Die Pharmazie 20100201
Olmesartan medoxomil evaluated for safety and efficacy in Indian patients with essential hypertension: a real world observational postmarketing surveillance.	The Journal of the Association of Physicians of India 20100201
Use of multiattribute utility theory for formulary management in a health system.	American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20100115
Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.	Diabetologia 20100101
Effects of olmesartan on Apelin/APJ and Akt/endothelial nitric oxide synthase pathway in Dahl rats with end-stage heart failure.	Journal of cardiovascular pharmacology 20100101
Medicinal chemistry of drugs used in diabetic cardiomyopathy.	Current medicinal chemistry 20100101
Efficacy of an olmesartan medoxomil-based treatment algorithm in patients stratified by age, race, or sex.	Journal of clinical hypertension (Greenwich, Conn.) 20100101
Cardioprotective effects of angiotensin II type 1 receptor blockade with olmesartan on reperfusion injury in a rat myocardial ischemia-reperfusion model.	Cardiovascular therapeutics 20100101
Doing what comes naturally.	Journal of general internal medicine 20100101
Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data.	American journal of cardiovascular drugs : drugs, devices, and other interventions 20100101
Renoprotective effect of calcium channel blockers in combination with an angiotensin receptor blocker in elderly patients with hypertension. A randomized crossover trial between benidipine and amlodipine.	Clinical and experimental hypertension (New York, N.Y. : 1993) 20100101
Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients.	Advances in therapy 20100101
Clinical and pharmacotherapeutic relevance of the double-chain domain of the angiotensin II type 1 receptor blocker olmesartan.	Clinical and experimental hypertension (New York, N.Y. : 1993) 20100101
Cyanobacterial cyclopeptides as lead compounds to novel targeted cancer drugs.	Marine drugs 20100101
New standards in hypertension and cardiovascular risk management: focus on telmisartan.	Vascular health and risk management 20100101
Development of a cell-based high-throughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3.	Current chemical genomics 20100101
Effects of telmisartan vs olmesartan on metabolic parameters, insulin resistance and adipocytokines in hypertensive obese patients.	Nutricion hospitalaria 20100101
Olmesartan inhibits angiotensin II-Induced migration of vascular smooth muscle cells through Src and mitogen-activated protein kinase pathways.	Journal of pharmacological sciences 20100101
Safety and tolerability of an olmesartan medoxomil-based regimen in patients with stage 1 hypertension: a randomized, double-blind, placebo-controlled study.	Clinical drug investigation 20100101
Use of evidence-based pharmacotherapy after myocardial infarction in Estonia.	BMC public health 20100101
Spectrophotometric estimation of olmesartan medoxomil and hydrochlorothiazide in tablet.	Indian journal of pharmaceutical sciences 20100101
Efficacy and safety of olmesartan medoxomil 40 mg/hydrochlorothiazide 12.5 mg combination therapy versus olmesartan medoxomil 40 mg monotherapy in patients with moderate to severe hypertension: a randomized, double-blind, parallel-group, multicentre, multinational, phase III study.	Clinical drug investigation 20100101
Involvement of TAGE-RAGE System in the Pathogenesis of Diabetic Retinopathy.	Journal of ophthalmology 20100101
Rhizoma Coptidis inhibits LPS-induced MCP-1/CCL2 production in murine macrophages via an AP-1 and NFkappaB-dependent pathway.	Mediators of inflammation 20100101
Effect of an olmesartan medoxomil-based treatment algorithm on systolic blood pressure in patients with stage 1 or 2 hypertension: a randomized, double-blind, placebo-controlled study.	American journal of cardiovascular drugs : drugs, devices, and other interventions 20100101
Impact of medical therapy on atheroma volume measured by different cardiovascular imaging modalities.	Cardiology research and practice 20100101
An olmesartan medoxomil-based treatment algorithm is effective in achieving 24-hour BP control in patients with type 2 diabetes mellitus, regardless of age, race, sex, or severity of hypertension: subgroup analysis of the BENIFICIARY study.	American journal of cardiovascular drugs : drugs, devices, and other interventions 20100101
Advanced glycation end products, oxidative stress and diabetic nephropathy.	Oxidative medicine and cellular longevity 20100101
Do we need more than just powerful blood pressure reductions? New paradigms in end-organ protection.	Vascular health and risk management 20100101
The bedtime administration ameliorates blood pressure variability and reduces urinary albumin excretion in amlodipine-olmesartan combination therapy.	Clinical and experimental hypertension (New York, N.Y. : 1993) 20100101
Role of olmesartan in combination therapy in blood pressure control and vascular function.	Vascular health and risk management 20100101
Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practice.	Vascular health and risk management 20100101
Olmesartan associated with acute renal failure in a patient with bilateral renal artery stenosis.	Renal failure 20100101
Renal protection in diabetes: lessons from ONTARGET.	Cardiovascular diabetology 20100101
Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma.	BMC cancer 20100101
Acute hepatocellular and cholestatic injury during therapy with hydrochlorothiazide - clinicohistopathologic findings: a case report.	Journal of medical case reports 20100101
Aging impairs myocardium-induced dilation in coronary arterioles: role of hydrogen peroxide and angiotensin.	Mechanisms of ageing and development 20100101
Complete disruption of all nitric oxide synthase genes causes markedly accelerated renal lesion formation following unilateral ureteral obstruction in mice in vivo.	Journal of pharmacological sciences 20100101
Attenuation of salt-induced cardiac remodeling and diastolic dysfunction by the GPER agonist G-1 in female mRen2.Lewis rats.	PloS one 20100101
Efficacy of combination therapy with telmisartan plus amlodipine in patients with poorly controlled hypertension.	Oxidative medicine and cellular longevity 20100101
Cardio classics revisited--focus on the role of candesartan.	Vascular health and risk management 20100101
Pilot study: rapidly cycling hypobaric pressure improves pain after 5 days in adiposis dolorosa.	Journal of pain research 20100101
Effects of angiotensin receptor blocker and calcium channel blocker on experimental abdominal aortic aneurysms in a hamster model.	The Kurume medical journal 20100101
Update on the role of candesartan in the optimal management of hypertension and cardiovascular risk reduction.	Integrated blood pressure control 20100101
Critical appraisal of the differential effects of antihypertensive agents on arterial stiffness.	Integrated blood pressure control 20100101
Impact of telmisartan in modifying vascular risk.	Integrated blood pressure control 20100101
Critical appraisal of amlodipine and olmesartan medoxomil fixed-dose combination in achieving blood pressure goals.	Integrated blood pressure control 20100101
Impact of olmesartan on blood pressure, endothelial function, and cardiovascular outcomes.	Integrated blood pressure control 20100101
Safety and tolerability of fixed antihypertensive combinations in blood pressure control: focus on olmesartan medoxomil and amlodipine combination.	Integrated blood pressure control 20100101
Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects.	Fundamental & clinical pharmacology 20091201
Olmesartan reduces oxidative stress in the brain of stroke-prone spontaneously hypertensive rats assessed by an in vivo ESR method.	Hypertension research : official journal of the Japanese Society of Hypertension 20091201
Angiotensin II and hypertonicity modulate proximal tubular aquaporin 1 expression.	American journal of physiology. Renal physiology 20091201
Angiotensin receptor blocker prevented beta-amyloid-induced cognitive impairment associated with recovery of neurovascular coupling.	Hypertension (Dallas, Tex. : 1979) 20091201
A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: the REZALT study.	Hypertension research : official journal of the Japanese Society of Hypertension 20091201
Ratio spectra derivative and zero-crossing difference spectrophotometric determination of olmesartan medoxomil and hydrochlorothiazide in combined pharmaceutical dosage form.	AAPS PharmSciTech 20091201
Effect of the angiotensin II type 1 receptor antagonist olmesartan on cerebral hemodynamics and rehabilitation outcomes in hypertensive post-stroke patients.	Brain injury 20091201
Evaluation for antioxidant and renoprotective activity of olmesartan using nephrectomy rats.	Biological & pharmaceutical bulletin 20091201
Gateways to clinical trials.	Methods and findings in experimental and clinical pharmacology 20091201
Mmp-9, a potential target for cerebral ischemic treatment.	Current neuropharmacology 20091201
Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.	Hypertension research : official journal of the Japanese Society of Hypertension 20091101
Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication use.	Journal of cardiovascular pharmacology 20091101
Benefits of the angiotensin II receptor antagonist olmesartan in controlling hypertension and cerebral hemodynamics after stroke.	Hypertension research : official journal of the Japanese Society of Hypertension 20091101
Effects of angiotensin II receptor blockers on the relationships between ambulatory blood pressure and anti-hypertensive effects, autonomic function, and health-related quality of life.	Clinical and experimental hypertension (New York, N.Y. : 1993) 20091101
Solubilized formulation of olmesartan medoxomil for enhancing oral bioavailability.	Archives of pharmacal research 20091101
Gateways to clinical trials.	Methods and findings in experimental and clinical pharmacology 20091101
Olmesartan medoxomil ameliorates sciatic nerve regeneration in diabetic rats.	Neuroreport 20091028
A sartan derivative with a very low angiotensin II receptor affinity ameliorates ischemic cerebral damage.	Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20091001
Multivalent ligand-receptor interactions elicit inverse agonist activity of AT(1) receptor blockers against stretch-induced AT(1) receptor activation.	Hypertension research : official journal of the Japanese Society of Hypertension 20091001
Significance of angiotensin II receptor blockers with high affinity to angiotensin II type 1 receptors for vascular protection in rats.	Hypertension research : official journal of the Japanese Society of Hypertension 20091001
Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients.	Hypertension (Dallas, Tex. : 1979) 20091001
Central blood pressure under angiotensin and calcium channel blockade.	Hypertension (Dallas, Tex. : 1979) 20091001
Does treatment with olmesartan improve arterial stenoses due to fibromuscular dysplasia?	Hypertension research : official journal of the Japanese Society of Hypertension 20091001
Combination of chronic exercise and antihypertensive therapy enhances renoprotective effects in rats with renal ablation.	American journal of hypertension 20091001
Estimating antihypertensive effects of combination therapy in an observational study using marginal structural models.	Biometrical journal. Biometrische Zeitschrift 20091001
[New developments in glaucoma medical treatment].	Archivos de la Sociedad Espanola de Oftalmologia 20091001
Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension.	Journal of atherosclerosis and thrombosis 20091001
Gateways to clinical trials.	Methods and findings in experimental and clinical pharmacology 20091001
Culture period-dependent change of function and expression of ATP-binding cassette transporters in Caco-2 cells.	Drug metabolism and disposition: the biological fate of chemicals 20090901
Re: Efficacy and safety of the single pill combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not controlled by amlodipine 10 mg plus olmesartan 20 mg in free combination.	Current medical research and opinion 20090901
Efficacy in angiotensin receptor blockade: a comparative review of data with olmesartan.	Journal of the renin-angiotensin-aldosterone system : JRAAS 20090901
Renoprotective effects of an angiotensin II receptor blocker in experimental model rats with hypertension and metabolic disorders.	Hypertension research : official journal of the Japanese Society of Hypertension 20090901
AT(1) receptor blockers increase insulin-like growth factor-I production by stimulating sensory neurons in spontaneously hypertensive rats.	Translational research : the journal of laboratory and clinical medicine 20090901
Olmesartan medoxomil: recent clinical and experimental acquisitions.	Expert opinion on drug metabolism & toxicology 20090901
Contribution of chymase-dependent angiotensin II formation to the progression of tubulointerstitial fibrosis in obstructed kidneys in hamsters.	Journal of pharmacological sciences 20090901
Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension.	Journal of clinical hypertension (Greenwich, Conn.) 20090901
Reversing bacteria-induced vitamin D receptor dysfunction is key to autoimmune disease.	Annals of the New York Academy of Sciences 20090901
Gateways to clinical trials.	Methods and findings in experimental and clinical pharmacology 20090901
[Sevikar or Forzaten: olmesartan medoxomil and amlodipine besylate fixed combination in the treatment of hypertension].	Revue medicale de Liege 20090901
Role of activated intrarenal reactive oxygen species and renin-angiotensin system in IgA nephropathy model mice.	Clinical and experimental pharmacology & physiology 20090801
Guanylyl cyclase-A inhibits angiotensin II type 2 receptor-mediated pro-hypertrophic signaling in the heart.	Endocrinology 20090801
Circulating angiopoietin-2 in essential hypertension: relation to atherosclerosis, vascular inflammation, and treatment with olmesartan/pravastatin.	Journal of hypertension 20090801
Reduction in urinary excretion of neutrophil gelatinase-associated lipocalin by angiotensin receptor blockers in hypertensive patients.	Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20090801
The involvement of aldosterone in cyclic stretch-mediated activation of NADPH oxidase in vascular smooth muscle cells.	Hypertension research : official journal of the Japanese Society of Hypertension 20090801
Improvement of glucose intolerance by combination of pravastatin and olmesartan in type II diabetic KK-A(y) mice.	Hypertension research : official journal of the Japanese Society of Hypertension 20090801
Renal and vascular glutathione S-transferase mu is not affected by pharmacological intervention to reduce systolic blood pressure.	Journal of hypertension 20090801
Direct action of an angiotensin II receptor blocker on angiotensin II-induced left atrial conduction delay in spontaneously hypertensive rats.	Hypertension research : official journal of the Japanese Society of Hypertension 20090801
Comparison of olmesartan medoxomil versus amlodipine besylate on regression of ventricular and vascular hypertrophy.	The American journal of cardiology 20090801
Treatment of hypertension in metabolic syndrome subjects with amlodipine and olmesartan-effects on oxidized non-esterified free fatty acids and cytokine production.	Cardiovascular drugs and therapy 20090801
Amlodipine besylate/olmesartan medoximil fixed combination for the treatment of hypertension.	Expert review of cardiovascular therapy 20090801
The effects of an olmesartan medoxomil-based treatment algorithm on 24-hour blood pressure levels in elderly patients aged 65 and older.	Journal of clinical hypertension (Greenwich, Conn.) 20090801
24-hour and nighttime blood pressures in type 2 diabetic hypertensive patients following morning or evening administration of olmesartan.	Journal of clinical hypertension (Greenwich, Conn.) 20090801
Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).	Hypertension research : official journal of the Japanese Society of Hypertension 20090701
Effects of combined olmesartan and pravastatin on glucose intolerance and cardiovascular remodeling in a metabolic-syndrome model.	Hypertension research : official journal of the Japanese Society of Hypertension 20090701
Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation.	Hypertension research : official journal of the Japanese Society of Hypertension 20090701
Mechanism of diastolic stiffening of the failing myocardium and its prevention by angiotensin receptor and calcium channel blockers.	Journal of cardiovascular pharmacology 20090701
Olmesartan ameliorates myocardial function independent of blood pressure control in patients with mild-to-moderate hypertension.	Heart and vessels 20090701
Study of the acute cardiovascular effects of several antihypertensive agents with the measurement of plasma catecholamines in mice.	Analytical and bioanalytical chemistry 20090601
Diabetes mellitus accelerates left ventricular diastolic dysfunction through activation of the renin-angiotensin system in hypertensive rats.	Hypertension research : official journal of the Japanese Society of Hypertension 20090601
Blockade of angiotensin II type-1 receptor increases salt sensitivity in Sprague-Dawley rats.	Hypertension research : official journal of the Japanese Society of Hypertension 20090601
Did Dr. & nurse fail notify pregnant Pt. to D/C Benicar? Mobile OB-GYN, PC. v. Baggett, 2009-AL-0615.006 (6/12/2009)-AL.	Nursing law's Regan report 20090601
Gateways to clinical trials.	Methods and findings in experimental and clinical pharmacology 20090601
Angiotensin II type 1 receptor blocker attenuates the activation of ERK and NADPH oxidase by mechanical strain in mesangial cells in the absence of angiotensin II.	American journal of physiology. Renal physiology 20090501
Effects of angiotensin II receptor blockers on relationships between 24-hour blood pressure, autonomic function, and health-related QOL.	Clinical and experimental hypertension (New York, N.Y. : 1993) 20090501
Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach.	International journal of clinical practice 20090501
Favorable cardiac and aortic remodeling in olmesartan-treated spontaneously hypertensive rats.	Heart and vessels 20090501
Pharmacokinetic and safety profile of olmesartan medoxomil in healthy Chinese subjects after single and multiple administrations.	Die Pharmazie 20090501
Olmesartan clinical trial in Okinawan patients under OKIDS (OCTOPUS) study: design and methods.	Clinical and experimental nephrology 20090401
Olmesartan improves left ventricular function in pressure-overload hypertrophied rat heart by blocking angiotensin II receptor with synergic effects of upregulation of angiotensin converting enzyme 2.	Therapeutic advances in cardiovascular disease 20090401
Influence of guidelines on physicians' assessment of blood pressure lowering effects and achievement rate of blood pressure target during transitional period of guidelines.	Clinical and experimental hypertension (New York, N.Y. : 1993) 20090401
Blood pressure-lowering effects of angiotensin receptor antagonist monotherapy and in combination with other anti-hypertensive drugs in primary care settings in Japan.	Clinical and experimental hypertension (New York, N.Y. : 1993) 20090401
Gateways to clinical trials.	Methods and findings in experimental and clinical pharmacology 20090401
Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors.	Drug metabolism and disposition: the biological fate of chemicals 20090301
Angiotensin II reduces mitochondrial content in skeletal muscle and affects glycemic control.	Diabetes 20090301
Efficacy and safety of olmesartan medoxomil alone and in combination with hydrochlorothiazide.	Expert review of cardiovascular therapy 20090301
Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: an emerging strategy in hypertension therapy.	Postgraduate medicine 20090301
Complementary mechanisms of angiotensin receptor blockers and calcium channel blockers in managing hypertension.	Postgraduate medicine 20090301
Activated intrarenal reactive oxygen species and renin angiotensin system in IgA nephropathy.	Minerva urologica e nefrologica = The Italian journal of urology and nephrology 20090301
Pharmacokinetics of olmesartan medoxomil in hemodialysis patients: little effect of dialysis upon its pharmacokinetics.	Clinical and experimental nephrology 20090201
Continuous activation of renin-angiotensin system impairs cognitive function in renin/angiotensinogen transgenic mice.	Hypertension (Dallas, Tex. : 1979) 20090201
Prevention of vascular injury by combination of an AT1 receptor blocker, olmesartan, with various calcium antagonists.	American journal of hypertension 20090201
Angiotensin II receptor blockade inhibits acute glomerular injuries with the alteration of receptor expression.	Laboratory investigation; a journal of technical methods and pathology 20090201
Efficacy and safety of the single pill combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not controlled by amlodipine 10 mg plus olmesartan 20 mg in free combination.	Current medical research and opinion 20090201
Olmesartan and temocapril prevented the development of hyperglycemia and the deterioration of pancreatic islet morphology in Otsuka-Long-Evans-Tokushima Fatty rats.	Acta medica Okayama 20090201
Rationale, study design and implementation of the COLM study: the combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients.	Hypertension research : official journal of the Japanese Society of Hypertension 20090201
Effects of angiotensin II type 1 receptor blocker on albumin-induced cell damage in human renal proximal tubular epithelial cells.	American journal of nephrology 20090101

Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.

The American journal of medicine 20121001

The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.

Diabetes & vascular disease research 20121001

Development and characterization of colloidal soft nano-carriers for transdermal delivery and bioavailability enhancement of an angiotensin II receptor blocker.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20121001

Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis.

American journal of cardiovascular drugs : drugs, devices, and other interventions 20121001

Efficacy of olmesartan medoxomil and hydrochlorothiazide fixed-dose combination therapy in patients aged 65 years and older with stage 1 and 2 hypertension or isolated systolic hypertension.

American journal of cardiovascular drugs : drugs, devices, and other interventions 20121001

Using different methods to evaluate the efficacy of olmesartan medoxomil in Chinese patients with mild to moderate essential hypertension according to ambulatory blood pressure monitoring.

Blood pressure monitoring 20121001

Electrochemical determination of olmesartan medoxomil using hydrothermally prepared nanoparticles composed SnO2-Co3O4 nanocubes in tablet dosage forms.

Talanta 20120915

Determination of eprosartan mesylate and hydrochlorothiazide in tablets by derivative spectrophotometric and high-performance liquid chromatographic methods.

Journal of chromatographic science 20120901

Stability-indicating method for simultaneous estimation of olmesartan medoxomile, amlodipine besylate and hydrochlorothiazide by RP-HPLC in tablet dosage form.

Journal of chromatographic science 20120901

High glucose potentiates and renin-angiotensin blockade downregulates LPS-induced tissue factor expression in human mononuclear cells.

Thrombosis research 20120901

Azilsartan medoxomil: a review of its use in hypertension.

Clinical drug investigation 20120901

Update on the ROADMAP clinical trial report: olmesartan for the prevention or delay of microalbuminuria development in type 2 diabetes.

Expert review of cardiovascular therapy 20120901

Angiotensin II-mediated up-regulation of connective tissue growth factor promotes atrial tissue fibrosis in the canine atrial fibrillation model.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 20120801

Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts.

Journal of cardiovascular pharmacology 20120801

Association study of genetic polymorphisms of drug transporters, SLCO1B1, SLCO1B3 and ABCC2, in African-Americans, Hispanics and Caucasians and olmesartan exposure.

Journal of human genetics 20120801

Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension.

Hypertension (Dallas, Tex. : 1979) 20120801

Severe spruelike enteropathy associated with olmesartan.

Mayo Clinic proceedings 20120801

Triple-Combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in black and non-black study participants with hypertension: the TRINITY randomized, double-blind, 12-week, parallel-group study.

American journal of cardiovascular drugs : drugs, devices, and other interventions 20120801

Nebivolol does not protect against 5/6 ablation/infarction induced chronic kidney disease in rats - comparison with angiotensin II receptor blockade.

Life sciences 20120726

Effects of angiotensin receptor blockers on endothelial nitric oxide release: the role of eNOS variants.

British journal of clinical pharmacology 20120701

Influence of ABCC2, SLCO1B1, and ABCG2 polymorphisms on the pharmacokinetics of olmesartan.

Journal of cardiovascular pharmacology 20120701

Enhanced intrarenal receptor-mediated prorenin activation in chronic progressive anti-thymocyte serum nephritis rats on high salt intake.

American journal of physiology. Renal physiology 20120701

Olmesartan medoxomil treatment potently improves cardiac myosin-induced dilated cardiomyopathy via the modulation of ACE-2 and ANG 1-7 mas receptor.

Free radical research 20120701

Short-term suppression of the renin-angiotensin system in mice associated with hypertension during pregnancy.

Molecular medicine reports 20120701

Twenty-four hour and early morning blood pressure control of olmesartan vs. ramipril in elderly hypertensive patients: pooled individual data analysis of two randomized, double-blind, parallel-group studies.

Journal of hypertension 20120701

Olmesartan for the prevention or delay of diabetic nephropathy: some considerations.

Revista espanola de cardiologia (English ed.) 20120701

Possible involvement of angiotensin-converting enzyme 2 and Mas activation in inhibitory effects of angiotensin II Type 1 receptor blockade on vascular remodeling.

Hypertension (Dallas, Tex. : 1979) 20120701

Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease.

International urology and nephrology 20120601

Predictors of proteinuria reduction by monotherapy with an angiotensin receptor blocker, olmesartan.

Journal of the renin-angiotensin-aldosterone system : JRAAS 20120601

Olmesartan medoxomil in children and adolescents with hypertension†: profile report.

Paediatric drugs 20120601

Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study.

Hypertension (Dallas, Tex. : 1979) 20120601

Calcium antagonist added to angiotensin receptor blocker: a recipe for reducing blood pressure variability?: evidence from day-by-day home blood pressure monitoring.

Hypertension (Dallas, Tex. : 1979) 20120601

Efficacy/safety of olmesartan medoxomil versus losartan potassium in naïve versus previously treated subjects with hypertension.

Advances in therapy 20120601

Combined effects of up- and downstream therapies on atrial fibrillation in a canine rapid stimulation model.

International journal of cardiology 20120531

Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.

Journal of medicinal chemistry 20120524

Effective blockade of RAAS by combination of aliskiren and olmesartan improves glucose homeostasis, glomerular filtration rate along with renal variables in streptozotocin induced diabetic rats.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20120512

In situ intestinal permeability and in vivo absorption characteristics of olmesartan medoxomil in self-microemulsifying drug delivery system.

Drug development and industrial pharmacy 20120501

Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study.

Hypertension research : official journal of the Japanese Society of Hypertension 20120501

Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats.

American journal of hypertension 20120501

Management of blood pressure in children.

Current opinion in nephrology and hypertension 20120501

Heart angiotensin II-induced cardiomyocyte hypertrophy suppresses coronary angiogenesis and progresses diabetic cardiomyopathy.

American journal of physiology. Heart and circulatory physiology 20120501

Effect of nisoldipine and olmesartan on endothelium-dependent vasodilation in essential hypertensive patients.

CNS neuroscience & therapeutics 20120501

Blood pressure control with angiotensin receptor blocker-based three-drug combinations: key trials.

Advances in therapy 20120501

Efficacy/safety of olmesartan medoxomil versus losartan potassium in patients by stage 1 or 2 hypertension.

Postgraduate medicine 20120501

Reduction of the morning blood pressure surge treated with olmesartan in Chinese patients with mild to moderate essential hypertension--a multicenter, open-label, single treatment group clinical study.

European review for medical and pharmacological sciences 20120501

Olmesartan attenuates the development of heart failure after experimental autoimmune myocarditis in rats through the modulation of ANG 1-7 mas receptor.

Molecular and cellular endocrinology 20120404

Angiotensin II receptor blocker combinations: from guidelines to clinical practice.

Blood pressure 20120401

Increased mortality in patients with diabetes associated with olmesartan for the prevention/delay of microalbuminuria onset: a matter of concern?

Revista espanola de cardiologia (English ed.) 20120401

Revelation on the potency of α(1) -blockers - parallel blockade of angiotensin II receptor: a new finding.

Pharmaceutical biology 20120401

Effects of valsartan versus olmesartan addition to amlodipine/hydrochlorothiazide combination in treating stage 2 hypertensive patients.

Expert opinion on pharmacotherapy 20120401

Prevention of microalbuminuria in patients with type 2 diabetes and hypertension.

Journal of hypertension 20120401

Effect of an L- and T-type calcium channel blocker on 24-hour systolic blood pressure and heart rate in hypertensive patients.

Korean circulation journal 20120401

Angiotensin II receptor blocker partially ameliorated intrarenal hypoxia in chronic kidney disease patients: a pre-/post-study.

Internal medicine journal 20120401

[Hypertension: improved therapy adherence after switch to a fixed drug combinations].

MMW Fortschritte der Medizin 20120322

Renal sympathetic denervation suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation.

Circulation 20120320

Key advances in antihypertensive treatment.

Nature reviews. Cardiology 20120320

Activation of renal angiotensin type 1 receptor contributes to the pathogenesis of progressive renal injury in a rat model of chronic cardiorenal syndrome.

American journal of physiology. Renal physiology 20120315

Abilities of candesartan and other AT(1) receptor blockers to impair angiotensin II-induced AT(1) receptor activation after wash-out.

Journal of the renin-angiotensin-aldosterone system : JRAAS 20120301

Protective actions of nebivolol on chronic nitric oxide synthase inhibition-induced hypertension and chronic kidney disease in the rat: a comparison with angiotensin II receptor blockade.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20120301

Addition of aliskiren to olmesartan ameliorates tubular injury in chronic kidney disease patients partly by reducing proteinuria.

Journal of the renin-angiotensin-aldosterone system : JRAAS 20120301

Aldosterone does not contribute to renal p21 expression during the development of angiotensin II-induced hypertension in mice.

American journal of hypertension 20120301

Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension.

Journal of clinical hypertension (Greenwich, Conn.) 20120301

The role of ARBs alone or with HCTZ in the treatment of hypertension and prevention of cardiovascular and renal complications.

Postgraduate medicine 20120301

Modulation of renal superoxide dismutase by telmisartan therapy in C57BL/6-Ins2(Akita) diabetic mice.

Hypertension research : official journal of the Japanese Society of Hypertension 20120201

Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.

Drug metabolism and disposition: the biological fate of chemicals 20120201

Olmesartan medoxomil combined with hydrochlorothiazide improves 24-hour blood pressure control in moderate-to-severe hypertension.

Current medical research and opinion 20120201

Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial.

Circulation. Arrhythmia and electrophysiology 20120201

Development of safety profile evaluating pharmacokinetics, pharmacodynamics and toxicity of a combination of pioglitazone and olmesartan medoxomil in Wistar albino rats.

Regulatory toxicology and pharmacology : RTP 20120201

The use of modeling and simulation to guide clinical development of olmesartan medoxomil in pediatric subjects.

Clinical pharmacology and therapeutics 20120201

Direct angiotensin II type 2 receptor stimulation in Nω-nitro-L-arginine-methyl ester-induced hypertension: the effect on pulse wave velocity and aortic remodeling.

Hypertension (Dallas, Tex. : 1979) 20120201

Olmesartan/amlodipine: blood pressure lowering and beyond in special populations.

Therapeutic advances in cardiovascular disease 20120201

Effects of olmesartan and imidapril on the plasma adiponectin, P-selectin, and MDA-LDL levels of diabetic nephropathy patients.

Clinica chimica acta; international journal of clinical chemistry 20120118

Modulation of AT-1R/MAPK cascade by an olmesartan treatment attenuates diabetic nephropathy in streptozotocin-induced diabetic mice.

Molecular and cellular endocrinology 20120102

Losartan modulates muscular capillary density and reverses thiazide diuretic-exacerbated insulin resistance in fructose-fed rats.

Hypertension research : official journal of the Japanese Society of Hypertension 20120101

Olmesartan medoxomil treatment is associated with decreased plasma B-type natriuretic peptide levels in patients on hemodialysis.

Clinical and experimental hypertension (New York, N.Y. : 1993) 20120101

Olmesartan medoxomil and azelnidipine therapy in patients with hypertension and chronic kidney disease in Japan.

Journal of nephrology 20120101

Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study.

Journal of the American Society of Hypertension : JASH 20120101

Efficacy and tolerability of the single-pill combination of aliskiren 300 mg/amlodipine 10 mg in hypertensive patients not controlled by olmesartan 40 mg/amlodipine 10 mg.

Current medical research and opinion 20120101

Four-year clinical outcomes of the OLIVUS-Ex (impact of Olmesartan on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) extension trial.

Atherosclerosis 20120101

Endoplasmic reticulum stress and diabetic cardiomyopathy.

Experimental diabetes research 20120101

Olmesartan medoxomil is associated with decreased plasma AGEs, pentosidine, and N-(epsilon)-carboxymethyl-lysine levels in hemodialysis patients.

Clinical and experimental hypertension (New York, N.Y. : 1993) 20120101

Development of a novel 96-microwell assay with high throughput for determination of olmesartan medoxomil in its tablets.

Chemistry Central journal 20120101

Silicosis caused by chronic inhalation of snail shell powder.

Journal of Korean medical science 20120101

Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension.

Clinical and experimental hypertension (New York, N.Y. : 1993) 20120101

Cardio classics revisited: focus on the role of amlodipine.

Integrated blood pressure control 20120101

Involvement of PPAR-γ in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease.

Journal of neuroinflammation 20120101

How full is our antihypertensives pipeline?

Journal of pharmacology & pharmacotherapeutics 20120101

Secondary metabolites of Cynodon dactylon as an antagonist to angiotensin II type1 receptor: Novel in silico drug targeting approach for diabetic retinopathy.

Journal of pharmacology & pharmacotherapeutics 20120101

Solubilization of beclomethasone dipropionate in sterically stabilized phospholipid nanomicelles (SSMs): physicochemical and in vitro evaluations.

Drug design, development and therapy 20120101

Differential pharmacology and benefit/risk of azilsartan compared to other sartans.

Vascular health and risk management 20120101

Adoption of new drugs by physicians: a survival analysis.

BMC health services research 20120101

Therapeutic options for the treatment of hypertension in children and adolescents.

Clinical medicine insights. Circulatory, respiratory and pulmonary medicine 20120101

Olmesartan attenuates the impairment of endothelial cells induced by oxidized low density lipoprotein through downregulating expression of LOX-1.

International journal of molecular sciences 20120101

[Recent advance in kidney and hypertension research].

Nihon Jinzo Gakkai shi 20120101

Sex differences in primary hypertension.

Biology of sex differences 20120101

Proton and carbon ion radiotherapy for primary brain tumors delivered with active raster scanning at the Heidelberg Ion Therapy Center (HIT): early treatment results and study concepts.

Radiation oncology (London, England) 20120101

Major risk factors for the appearance of white-matter lesions on MRI in hypertensive patients with controlled blood pressure.

Vascular health and risk management 20120101

New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil.

Integrated blood pressure control 20120101

Combination therapy of olmesartan and azelnidipine inhibits sympathetic activity associated with reducing oxidative stress in the brain of hypertensive rats.

Clinical and experimental hypertension (New York, N.Y. : 1993) 20120101

Strategies to reverse endothelial progenitor cell dysfunction in diabetes.

Experimental diabetes research 20120101

The effect of antihypertensive drugs on endothelial function as assessed by flow-mediated vasodilation in hypertensive patients.

International journal of vascular medicine 20120101

What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment?

Cardiovascular diabetology 20120101

Emerging drug combinations to optimize renovascular protection and blood pressure goals.

International journal of nephrology and renovascular disease 20120101

Reciprocal interaction between macrophages and T cells stimulates IFN-γ and MCP-1 production in Ang II-induced cardiac inflammation and fibrosis.

PloS one 20120101

Different stability-indicating chromatographic techniques for the determination of netobimin.

Journal of analytical methods in chemistry 20120101

Comparison of the efficacy and safety of irbesartan and olmesartan in patients with hypertension (EARTH study).

Clinical and experimental hypertension (New York, N.Y. : 1993) 20120101

The role of apelin on the alleviative effect of Angiotensin receptor blocker in unilateral ureteral obstruction-induced renal fibrosis.

Nephron extra 20120101

Understanding the mechanism of hepatic fibrosis and potential therapeutic approaches.

Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association 20120101

Out-of-office blood pressure: from measurement to control.

Integrated blood pressure control 20120101

Critical evaluation of the efficacy and tolerability of azilsartan.

Vascular health and risk management 20120101

Angiotensin II, Aldosterone, and Anti-Inflammatory Lymphocytes: Interplay and Therapeutic Opportunities.

International journal of hypertension 20120101

Effects of olmesartan on arterial stiffness in rats with chronic renal failure.

Cardiovascular diabetology 20120101

Small molecules with similar structures exhibit agonist, neutral antagonist or inverse agonist activity toward angiotensin II type 1 receptor.

PloS one 20120101

Calcium channel blockers, more than diuretics, enhance vascular protective effects of angiotensin receptor blockers in salt-loaded hypertensive rats.

PloS one 20120101

Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic.

Vascular health and risk management 20120101

Effects of olmesartan, an angiotensin II receptor blocker, on peripheral insulin sensitivity in Japanese subjects with type 2 diabetes and hypertension.

Internal medicine (Tokyo, Japan) 20120101

Olmesartan improves coronary flow reserve of hypertensive patients using coronary magnetic resonance imaging compared with amlodipine.

Cardiology 20120101

Three in one: safety, efficacy, and patient acceptability of triple fixed-dose combination medicine in the management of hypertension.

Patient preference and adherence 20120101

Modulation of AT-1R/CHOP-JNK-Caspase12 pathway by olmesartan treatment attenuates ER stress-induced renal apoptosis in streptozotocin-induced diabetic mice.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20111218

Effect of olmesartan on oxidative stress in hypertensive patients: mechanistic support to clinical trials derived evidence.

Blood pressure 20111201

Thermal, dynamic and structural properties of drug AT1 antagonist olmesartan in lipid bilayers.

Biochimica et biophysica acta 20111201

Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study.

Diabetologia 20111201

Chronic angiotensin receptor blockade suppresses intracardiac angiotensin II in angiotensin II-infused rats.

Experimental biology and medicine (Maywood, N.J.) 20111201

Attenuation of hypertension-mediated glomerulosclerosis in conjunction with increased angiotensin (1-7).

Therapeutic advances in cardiovascular disease 20111201

Azilsartan medoxomil: a new angiotensin II receptor antagonist for treatment of hypertension.

The Annals of pharmacotherapy 20111201

24-hour efficacy and safety of Triple-Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: the TRINITY ambulatory blood pressure substudy.

Journal of clinical hypertension (Greenwich, Conn.) 20111201

Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

PLoS computational biology 20111201

Prediction of drug combinations by integrating molecular and pharmacological data.

PLoS computational biology 20111201

Effect of Olmesartan on serum cystatin C levels in the patients with essential hypertension.

European review for medical and pharmacological sciences 20111201

[Series: Clinical study from Japan and its reflections; Olmesartan Reducing Incidence of Endstage Renal Disease in Diabetic Nephropathy Trial (ORIENT)].

Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20111110

Office and ambulatory pulse pressure--association with clinical characteristics and cardiovascular risk factors in normoalbuminuric patients with type 2 diabetes (ROADMAP study).

Journal of human hypertension 20111101

Effects of olmesartan on blood pressure and insulin resistance in hypertensive patients with sleep-disordered breathing.

Heart and vessels 20111101

Protective effects of L-type fatty acid-binding protein (L-FABP) in proximal tubular cells against glomerular injury in anti-GBM antibody-mediated glomerulonephritis.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20111101

The central mechanism underlying hypertension: a review of the roles of sodium ions, epithelial sodium channels, the renin-angiotensin-aldosterone system, oxidative stress and endogenous digitalis in the brain.

Hypertension research : official journal of the Japanese Society of Hypertension 20111101

Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.

European journal of pharmacology 20111101

Effects of 1-year administration of olmesartan on portal pressure and TGF-beta1 in selected patients with cirrhosis: a randomized controlled trial.

Journal of gastroenterology 20111101

Angiotensin receptor blockers shift the circadian rhythm of blood pressure by suppressing tubular sodium reabsorption.

American journal of physiology. Renal physiology 20111101

Role of angiotensin-converting enzyme 2 in cardiac hypertrophy induced by nitric oxide synthase inhibition.

Journal of hypertension 20111101

Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches.

European heart journal 20111101

Blood pressure outcomes in patients receiving angiotensin II receptor blockers in primary care: a comparative effectiveness analysis from electronic medical record data.

Journal of clinical hypertension (Greenwich, Conn.) 20111101

Azilsartan medoxomil: a new Angiotensin receptor blocker.

Clinical therapeutics 20111101

Single-pill triple-combination therapy: an alternative to multiple-drug treatment of hypertension.

Postgraduate medicine 20111101

A pilot study on the effect of telmisartan & ramipril on 24 h blood pressure profile & dipping pattern in type 1 diabetes patients with nephropathy.

The Indian journal of medical research 20111101

Alterations in adhesion junction precede gap junction remodelling during the development of heart failure in cardiomyopathic hamsters.

Cardiovascular research 20111001

The ROADMAP trial: olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.

Expert opinion on pharmacotherapy 20111001

Prepubertal angiotensin blockade exerts long-term therapeutic effect through sustained ATRAP activation in salt-sensitive hypertensive rats.

Journal of hypertension 20111001

The effect of amlodipine besylate, losartan potassium, olmesartan medoxomil, and other antihypertensives on central aortic blood pressure and biomarkers of vascular function.

Therapeutic advances in cardiovascular disease 20111001

Pharmacotherapy review of chronic pediatric hypertension.

Clinical therapeutics 20111001

Olmesartan, a novel angiotensin II type 1 receptor antagonist, reduces severity of atherosclerosis in apolipoprotein E deficient mice associated with reducing superoxide production.

Nutrition, metabolism, and cardiovascular diseases : NMCD 20110901

Effects of high dose olmesartan medoxomil plus hydrochlorothiazide on blood pressure control in patients with grade 2 and grade 3 hypertension.

Journal of human hypertension 20110901

Significance of pigment epithelium-derived factor levels with angiotensin II type 1 receptor blockers in patients with successful coronary stent implantation.

Journal of the renin-angiotensin-aldosterone system : JRAAS 20110901

Efficacy of Sevikar® compared to the combination of perindopril plus amlodipine on central arterial blood pressure in patients with moderate-to-severe hypertension: Rationale and design of the SEVITENSION study.

Contemporary clinical trials 20110901

Design, synthesis, bioconversion, and pharmacokinetics evaluation of new ester prodrugs of olmesartan.

European journal of medicinal chemistry 20110901

Long-term clinical and economic outcomes associated with angiotensin II receptor blocker use in hypertensive patients.

Current medical research and opinion 20110901

Seated cuff blood pressure-lowering efficacy of an olmesartan medoxomil-based treatment regimen in patients with type 2 diabetes mellitus.

Drugs in R&D 20110901

Severe angioedema associated with olmesartan.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20110901

Compliance, persistence, and switching patterns for ACE inhibitors and ARBs.

The American journal of managed care 20110901

[Case of olmesartan and amlodipine intoxication].

Chudoku kenkyu : Chudoku Kenkyukai jun kikanshi = The Japanese journal of toxicology 20110901

Design and rationale of Japanese evaluation between Formula of Azelnidipine and amlodipine add on olmesartan to Get antialbuminuric effect study (J-FLAG) : evaluation of the antialbuminuric effects between calcium channel blocker with sympatholytic action in hypertensive patients with diabetes and albuminuria.

Cardiovascular drugs and therapy 20110801

Sodium intake in men and potassium intake in women determine the prevalence of metabolic syndrome in Japanese hypertensive patients: OMEGA Study.

Hypertension research : official journal of the Japanese Society of Hypertension 20110801

Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.

Hypertension research : official journal of the Japanese Society of Hypertension 20110801

L-/T-type Ca channel blockers for kidney protection: ready for sophisticated use of Ca channel blockers.

Hypertension research : official journal of the Japanese Society of Hypertension 20110801

'ROADMAP' controversies.

Journal of clinical hypertension (Greenwich, Conn.) 20110801

Purification and identification of activating enzymes of CS-0777, a selective sphingosine 1-phosphate receptor 1 modulator, in erythrocytes.

The Journal of biological chemistry 20110715

Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients.

Heart and vessels 20110701

[Fixed drug combinations in hypertension: a budget impact analysis for the Spanish Health System on the marketing of a fixed combination of olmesartan/amlodipine].

Atencion primaria 20110701

Olmesartan ameliorates peripheral nerve dysfunction in Zucker diabetic fatty rats.

Journal of hypertension 20110701

Fixed-combination therapy to improve blood pressure control: experience with olmesartan-based therapy.

Expert review of cardiovascular therapy 20110701

The significance of the j-curve in hypertension and coronary artery diseases.

Korean circulation journal 20110701

Olmesartan, microalbuminuria, and type 2 diabetes.

The New England journal of medicine 20110609

Olmesartan, microalbuminuria, and type 2 diabetes.

The New England journal of medicine 20110609

Olmesartan, microalbuminuria, and type 2 diabetes.

The New England journal of medicine 20110609

Olmesartan, microalbuminuria, and type 2 diabetes.

The New England journal of medicine 20110609

Efficacy and safety of olmesartan medoxomil plus amlodipine in age, gender and hypertension severity defined subgroups of hypertensive patients.

Journal of human hypertension 20110601

Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study.

Journal of human hypertension 20110601

Olmesartan improves endothelial function in hypertensive patients: link with extracellular superoxide dismutase.

Hypertension research : official journal of the Japanese Society of Hypertension 20110601

Combining rosuvastatin with sartans of different peroxisome proliferator-activated receptor-γ activating capacity is not associated with different changes in low-density lipoprotein subfractions and plasma lipoprotein-associated phospholipase A₂.

Metabolic syndrome and related disorders 20110601

Role of intrarenal angiotensin system activation, oxidative stress, inflammation, and impaired nuclear factor-erythroid-2-related factor 2 activity in the progression of focal glomerulosclerosis.

The Journal of pharmacology and experimental therapeutics 20110601

The 'pyrrhic victory' of amlodipine over hydrochlorothiazide in the OLAS Study.

Journal of human hypertension 20110601

Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments.

Drug metabolism and disposition: the biological fate of chemicals 20110601

Changes in renal vessels following the long-term administration of an angiotensin II receptor blocker in Zucker fatty rats.

Journal of the renin-angiotensin-aldosterone system : JRAAS 20110601

The effect of antihypertensive agents in people at high risk of cardiovascular disease and diabetes: a view through smoke and mirrors.

Journal of human hypertension 20110601

Telmisartan exerts antiatherosclerotic effects by activating peroxisome proliferator-activated receptor-γ in macrophages.

Arteriosclerosis, thrombosis, and vascular biology 20110601

Mineralocorticoid receptor activation: a major contributor to salt-induced renal injury and hypertension in young rats.

American journal of physiology. Renal physiology 20110601

Pharmacotherapy: Olmesartan for microalbuminuria--friend or foe?

Nature reviews. Endocrinology 20110601

Estrogen-independent activation of estrogen receptors.

Hypertension (Dallas, Tex. : 1979) 20110601

Activation of estrogen receptor-α and of angiotensin-converting enzyme 2 suppresses ischemic brain damage in oophorectomized rats.

Hypertension (Dallas, Tex. : 1979) 20110601

Blood pressure-lowering efficacy of an olmesartan medoxomil/hydrochlorothiazide-based treatment algorithm in elderly patients (age ≥65 years) stratified by age, sex and race: subgroup analysis of a 12-week, open-label, single-arm, dose-titration study.

Drugs & aging 20110601

A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide.

Journal of clinical hypertension (Greenwich, Conn.) 20110601

Efficacy of amlodipine and olmesartan medoxomil in hypertensive patients with diabetes and obesity.

Journal of clinical hypertension (Greenwich, Conn.) 20110601

Epigallocatechin-3-gallate Regulates Inducible Nitric Oxide Synthase Expression in Human Umbilical Vein Endothelial Cells.

Laboratory animal research 20110601

Diabetes: ROADMAP: the road to renoprotection?

Nature reviews. Nephrology 20110524

Olmesartan severely weakened the development of NASH in an animal model of hypercholesterolemia.

Atherosclerosis 20110501

A pooled analysis of 20 post-authorization surveys of olmesartan involving 156,682 hypertensive patients.

Expert opinion on drug safety 20110501

Diabetes: olmesartan slows microalbuminuria.

Nature reviews. Cardiology 20110501

Long-term effects of Irbesartan treatment and smoking on nucleic acid oxidation in patients with type 2 diabetes and microalbuminuria: an Irbesartan in patients with type 2 diabetes and Microalbuminuria (IRMA 2) substudy.

Diabetes care 20110501

Angiotensin type 1 receptor blocker reduces intimal neovascularization and plaque growth in apolipoprotein E-deficient mice.

Hypertension (Dallas, Tex. : 1979) 20110501

Management of hypertension in patients with diabetes using an amlodipine-, olmesartan medoxomil-, and hydrochlorothiazide-based titration regimen.

The American journal of cardiology 20110501

Randomized Olmesartan And Diabetes Microalbuminuria Prevention Study (ROADMAP).

Polskie Archiwum Medycyny Wewnetrznej 20110501

The combination of amlodipine and angiotensin receptor blocker or diuretics in high-risk hypertensive patients: rationale, design and baseline characteristics.

Journal of human hypertension 20110401

Circadian rhythms in blood pressure regulation and optimization of hypertension treatment with ACE inhibitor and ARB medications.

American journal of hypertension 20110401

Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension.

Blood pressure. Supplement 20110401

Angiotensin II type 1 receptor blocker inhibits arterial calcification in a pre-clinical model.

Cardiovascular research 20110401

Telmisartan inhibits vasoconstriction via PPARγ-dependent expression and activation of endothelial nitric oxide synthase.

Cardiovascular research 20110401

Urinary albumin excretion during angiotensin II receptor blockade: comparison of combination treatment with a diuretic or a calcium-channel blocker.

American journal of hypertension 20110401

The role of ambulatory blood pressure monitoring compared with clinic and home blood pressure measures in evaluating moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy.

Blood pressure monitoring 20110401

Reduction of albuminuria with antihypertensive treatment: is more always better?

American journal of hypertension 20110401

Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: considerations on drug-drug interactions.

Biopharmaceutics & drug disposition 20110401

[Fixed dose combination of an ARB calcium antagonist lowers blood pressure effectively and improves quality of life].

MMW Fortschritte der Medizin 20110331

Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.

The New England journal of medicine 20110310

Preemptive olmesartan for the delay or prevention of microalbuminuria in diabetes.

The New England journal of medicine 20110310

Update on potential medical treatments for encapsulating peritoneal sclerosis; human and experimental data.

International urology and nephrology 20110301

In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies.

The Journal of pharmacology and experimental therapeutics 20110301

Comparison of combination therapies, including the angiotensin receptor blocker olmesartan and either a calcium channel blocker or a thiazide diuretic, in elderly patients with hypertension.

Hypertension research : official journal of the Japanese Society of Hypertension 20110301

Blockade of AT1 receptors protects the blood-brain barrier and improves cognition in Dahl salt-sensitive hypertensive rats.

American journal of hypertension 20110301

Association between aldosterone induced by antihypertensive medication and arterial stiffness reduction: the J-CORE study.

Atherosclerosis 20110301

Safety and efficacy of olmesartan: an observational pooled-analysis of 156,682 hypertensive patients.

Expert opinion on drug safety 20110301

Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.

Hypertension (Dallas, Tex. : 1979) 20110301

Triple-drug, fixed-dose combinations for the treatment of hypertension: focus on olmesartan/amlodipine/hydrochlorothiazide combination.

Drugs of today (Barcelona, Spain : 1998) 20110301

The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure.

Journal of clinical hypertension (Greenwich, Conn.) 20110201

Effects of angiotensin II receptor antagonist olmesartan on renal hemodynamic variables and vascular structural properties in streptozotocin-induced diabetic rats.

Chinese medical journal 20110201

Olmesartan medoxomil/amlodipine/hydrochlorothiazide: fixed-dose combination in hypertension.

Drugs 20110122

Co-treatment with azelinidipine and olmesartan inhibits advanced glycation end products (AGEs) elicited down-regulation of adiponectin mRNA levels in cultured adipocytes partly via its anti-oxidative property.

International journal of cardiology 20110121

Possible involvement of intracellular angiotensin II receptor in high-glucose-induced damage in renal proximal tubular cells.

Journal of nephrology 20110101

Possible Link between Metabolic Syndrome and Chronic Kidney Disease in the Development of Cardiovascular Disease.

Cardiology research and practice 20110101

Efficacy of olmesartan therapy on fibrinolytic capacity in patients with hypertension.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20110101

Comparative analysis of telmisartan and olmesartan on cardiac function in the transgenic (mRen2)27 rat.

American journal of physiology. Heart and circulatory physiology 20110101

Compliance, persistence, healthcare resource use, and treatment costs associated with aliskiren plus ARB versus ACE inhibitor plus ARB combination therapy: in US patients with hypertension.

American journal of cardiovascular drugs : drugs, devices, and other interventions 20110101

Olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide triple combination for hypertension.

Expert review of cardiovascular therapy 20110101

Effects of olmesartan medoxomil, an angiotensin II type 1 receptor antagonist, on plasma concentration of B-type natriuretic peptide, in hypertensive patients with type 2 diabetes mellitus: a preliminary, observational, open-label study.

Clinical drug investigation 20110101

Rodent models for metabolic syndrome research.

Journal of biomedicine & biotechnology 20110101

The development and the use of experimental animal models to study the underlying mechanisms of CA formation.

Journal of biomedicine & biotechnology 20110101

Angiotensin II receptor blocker induced fetopathy: 7 cases.

Klinische Padiatrie 20110101

Comparison of combination therapy of olmesartan plus azelnidipine or hydrochlorothiazide on renal and vascular damage in SHR/NDmcr-cp rats.

Kidney & blood pressure research 20110101

Chronopharmacology of angiotensin II-receptor blockers in stroke-prone spontaneously hypertensive rats.

Journal of pharmacological sciences 20110101

A randomized, double-blind, forced-titration study to compare olmesartan medoxomil versus losartan potassium in patients with stage 1 and 2 hypertension.

Postgraduate medicine 20110101

Central angiotensin II stimulation promotes β amyloid production in Sprague Dawley rats.

PloS one 20110101

Olmesartan, an AT1 antagonist, attenuates oxidative stress, endoplasmic reticulum stress and cardiac inflammatory mediators in rats with heart failure induced by experimental autoimmune myocarditis.

International journal of biological sciences 20110101

Use of Angiotensin receptor blockers in cardiovascular protection: current evidence and future directions.

P & T : a peer-reviewed journal for formulary management 20110101

Activation of Src mediates PDGF-induced Smad1 phosphorylation and contributes to the progression of glomerulosclerosis in glomerulonephritis.

PloS one 20110101

Hypertensive nephropathy treatment by heart-protecting musk pill: a study of anti-inflammatory therapy for target organ damage of hypertension.

International journal of general medicine 20110101

Moderate versus intensive treatment of hypertension using amlodipine/valsartan and with the addition of hydrochlorothiazide for patients uncontrolled on angiotensin receptor blocker monotherapy: results in racial/ethnic subgroups.

Journal of the American Society of Hypertension : JASH 20110101

HIV-1 accessory protein Vpr: relevance in the pathogenesis of HIV and potential for therapeutic intervention.

Retrovirology 20110101

Olmesartan medoxomil for the treatment of hypertension in children and adolescents.

Vascular health and risk management 20110101

Olmesartan/amlodipine: a review of its use in the management of hypertension.

Vascular health and risk management 20110101

Clinical utility of valsartan in the treatment of hypertension in children and adolescents.

Patient preference and adherence 20110101

Cardiovascular and Renal Links along the Cardiorenal Continuum.

International journal of nephrology 20110101

Adverse effect profile of trichlormethiazide: a retrospective observational study.

Cardiovascular diabetology 20110101

Combination delapril/manidipine as antihypertensive therapy in high-risk patients.

Clinical drug investigation 20110101

Novel ocular antihypertensive compounds in clinical trials.

Clinical ophthalmology (Auckland, N.Z.) 20110101

Reappraisal of role of angiotensin receptor blockers in cardiovascular protection.

Vascular health and risk management 20110101

A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors.

Vascular health and risk management 20110101

Mesenteric panniculitis presenting with acute non-occlusive colonic ischemia.

International archives of medicine 20110101

Choice of angiotensin receptor blocker in moderate hypertension. A UK-based cost-benefit comparison of olmesartan- and candesartan-based regimens.

Journal of medical economics 20110101

Olmesartan induces renoprotective effects by stimulating angiotensin type 2 receptors and reducing oxidative stress in diabetic nephropathy.

Kidney & blood pressure research 20110101

Differential Effects in Cardiovascular Markers between High-Dose Angiotensin II Receptor Blocker Monotherapy and Combination Therapy of ARB with Calcium Channel Blocker in Hypertension (DEAR Trial).

International journal of hypertension 20110101

Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study.

Vascular health and risk management 20110101

Cardiovascular outcomes with angiotensin II receptor blockers: clinical implications of recent trials.

Vascular health and risk management 20110101

Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil.

Vascular health and risk management 20110101

Animal models of calcific aortic valve disease.

International journal of inflammation 20110101

Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: a retrospective observational study.

Cardiovascular diabetology 20110101

Effects of olmesartan on the renin-angiotensin-aldosterone system for patients with essential hypertension after cardiac surgery--investigation using a candesartan change-over study.

Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia 20110101

Prevention and intervention studies with telmisartan, ramipril and their combination in different rat stroke models.

PloS one 20110101

Cardioprotective effects of telmisartan against heart failure in rats induced by experimental autoimmune myocarditis through the modulation of angiotensin-converting enzyme-2/angiotensin 1-7/mas receptor axis.

International journal of biological sciences 20110101

A critical appraisal of the clinical effectiveness of a fixed combination of valsartan, amlodipine, and hydrochlorothiazide in achieving blood pressure goals.

Integrated blood pressure control 20110101

Long-term use and tolerability of irbesartan for control of hypertension.

Integrated blood pressure control 20110101

Clinical utility of fixed-combination telmisartan-amlodipine in the treatment of hypertension.

Integrated blood pressure control 20110101

Development and characterization of nanosuspensions of olmesartan medoxomil for bioavailability enhancement.

Journal of pharmacy & bioallied sciences 20110101

Azilsartan: a newly approved angiotensin II receptor blocker.

Cardiology in review 20110101

Proteomic and biochemical analyses reveal the activation of unfolded protein response, ERK-1/2 and ribosomal protein S6 signaling in experimental autoimmune myocarditis rat model.

BMC genomics 20110101

Inverse agonism and its therapeutic significance.

Indian journal of pharmacology 20110101

Efficacy of fixed-dose amlodipine and losartan combination compared with amlodipine monotherapy in stage 2 hypertension: a randomized, double blind, multicenter study.

BMC research notes 20110101

Azelnidipine prevents cardiac dysfunction in streptozotocin-diabetic rats by reducing intracellular calcium accumulation, oxidative stress and apoptosis.

Cardiovascular diabetology 20110101

Hepatic mitochondrial dysfunction in Friedreich ataxia.

BMC neurology 20110101

Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk.

Vascular health and risk management 20110101

Lipid chaperones and metabolic inflammation.

International journal of inflammation 20110101

Peroxisome proliferator-activated receptor-gamma agonists suppress tissue factor overexpression in rat balloon injury model with paclitaxel infusion.

PloS one 20110101

Apelin and pulmonary hypertension.

Pulmonary circulation 20110101

[Multicenter trial of olmesartan. Main results].

Terapevticheskii arkhiv 20110101

Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ.

Vascular health and risk management 20110101

Changes in human fecal microbiota due to chemotherapy analyzed by TaqMan-PCR, 454 sequencing and PCR-DGGE fingerprinting.

PloS one 20110101

Differential clinical profile of candesartan compared to other angiotensin receptor blockers.

Vascular health and risk management 20110101

Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination.

Integrated blood pressure control 20110101

A pilot study to clinically evaluate the role of herbomineral compound 'Rakatchap Har' in the management of essential hypertension.

Ayu 20110101

Olmesartan medoxomil: in children and adolescents with hypertension.

Drugs 20101224

Long-term efficacy of a combination of amlodipine and olmesartan medoxomil ± hydrochlorothiazide in patients with hypertension stratified by age, race and diabetes status: a substudy of the COACH trial.

Journal of human hypertension 20101201

Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model.

Kidney international 20101201

Aliskiren, a renin inhibitor, downregulates TNF-α-induced tissue factor expression in HUVECS.

Journal of the renin-angiotensin-aldosterone system : JRAAS 20101201

Improving quality of life in hypertension management using a fixed-dose combination of olmesartan and amlodipine in primary care.

Expert opinion on pharmacotherapy 20101201

Comparison of angiotensin II type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice.

Hypertension research : official journal of the Japanese Society of Hypertension 20101201

Connective tissue growth factor induction in a pressure-overloaded heart ameliorated by the angiotensin II type 1 receptor blocker olmesartan.

Hypertension research : official journal of the Japanese Society of Hypertension 20101201

Development and validation of an LC-ESI-MS/MS method for simultaneous quantitation of olmesartan and pioglitazone in rat plasma and its pharmacokinetic application.

Biomedical chromatography : BMC 20101201

Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension.

Journal of human hypertension 20101101

The Renin-Angiotensin system mediates the effects of stretch on conduction velocity, connexin43 expression, and redistribution in intact ventricle.

Journal of cardiovascular electrophysiology 20101101

Coronary vascular dysfunction promoted by oxidative-nitrative stress in SHRSP.Z-Lepr(fa) /IzmDmcr rats with metabolic syndrome.

Clinical and experimental pharmacology & physiology 20101101

The counterregulating role of ACE2 and ACE2-mediated angiotensin 1-7 signaling against angiotensin II stimulation in vascular cells.

Hypertension research : official journal of the Japanese Society of Hypertension 20101101

Strong suppression of the renin-angiotensin system has a renal-protective effect in hypertensive patients: high-dose ARB with ACE inhibitor (Hawaii) study.

Hypertension research : official journal of the Japanese Society of Hypertension 20101101

Regression of superficial glomerular podocyte injury in type 2 diabetic rats with overt albuminuria: effect of angiotensin II blockade.

Journal of hypertension 20101101

Intrarenal suppression of angiotensin II type 1 receptor binding molecule in angiotensin II-infused mice.

American journal of physiology. Renal physiology 20101101

Beneficial effects of angiotensin II receptor blocker, olmesartan, in limiting the cardiotoxic effect of daunorubicin in rats.

Free radical research 20101101

Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study.

Journal of hypertension 20101101

Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

Bioorganic & medicinal chemistry letters 20101101

Beneficial effects of olmesartan, an angiotensin II receptor type 1 antagonist, in rats with dilated cardiomyopathy.

Experimental biology and medicine (Maywood, N.J.) 20101101

Spontaneous development of left ventricular hypertrophy and diastolic dysfunction in mice lacking all nitric oxide synthases.

Circulation journal : official journal of the Japanese Circulation Society 20101101

Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine.

British journal of cancer 20101101

Efficacy and safety of olmesartan medoxomil in patients with stage 1 hypertension: blood pressure lowering and goal achievement.

Postgraduate medicine 20101101

Metabolic regulation of coronary vascular tone: role of hydrogen peroxide, purinergic components, and angiotensin.

European journal of pharmacology 20101025

An angiotensin II type 1 receptor blocker can preserve endothelial function and attenuate brain ischemic damage in spontaneously hypertensive rats.

Journal of neuroscience research 20101001

A sensitive short-term evaluation of antifibrotic effects using newly established type I collagen reporter transgenic rats.

American journal of physiology. Renal physiology 20101001

Novel amides and esters prodrugs of olmesartan: Synthesis, bioconversion, and pharmacokinetic evaluation.

Bioorganic & medicinal chemistry letters 20101001

Efficacy of an olmesartan medoxomil-based treatment algorithm in patients with hypertension and type 2 diabetes: analysis of diurnal blood pressure control as assessed by 24-hour ambulatory blood pressure monitoring.

Therapeutic advances in cardiovascular disease 20101001

Efficacy and tolerability of olmesartan/amlodipine combination therapy in patients with mild-to-severe hypertension: focus on 24-h blood pressure control.

Therapeutic advances in cardiovascular disease 20101001

Tribenzor for hypertension.

The Medical letter on drugs and therapeutics 20100906

Chart review of patients on valsartan-based single-pill combinations vs. ARB-based free combinations for BP goal achievement.

Current medical research and opinion 20100901

Combination therapy for hypertension: focus on high-dose olmesartan medoxomil (40 mg) plus hydrochlorothiazide.

Expert opinion on pharmacotherapy 20100901

Effects of olmesartan vs irbesartan on metabolic parameters and visfatin in hypertensive obese women.

European review for medical and pharmacological sciences 20100901

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20100901

Porphyria cutanea tarda induced by olmesartan.

Journal of the European Academy of Dermatology and Venereology : JEADV 20100801

Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients.

Hypertension research : official journal of the Japanese Society of Hypertension 20100801

Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study.

Therapeutic advances in cardiovascular disease 20100801

Pharmacological therapy for hypertensive children: an 'additional bypass' of lifestyle interventions.

Hypertension (Dallas, Tex. : 1979) 20100801

Protective effects of angiotensin II type-1 receptor blockade with olmesartan on spinal cord ischemia-reperfusion injury: an experimental study on rats.

Annals of vascular surgery 20100801

Stability indicating LC method for the simultaneous determination of amlodipine and olmesartan in dosage form.

Journal of chromatographic science 20100801

Inhibitory effects of olmesartan on catecholamine secretion from the perfused rat adrenal medulla.

The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 20100801

The relative bioavailability and fasting pharmacokinetics of three formulations of olmesartan medoxomil 20-mg capsules and tablets in healthy Chinese male volunteers: An open-label, randomized-sequence, single-dose, three-way crossover study.

Clinical therapeutics 20100801

Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study.

Clinical therapeutics 20100701

Blockade of renin-angiotensin system attenuates advanced glycation end products-mediated signaling pathways.

Journal of atherosclerosis and thrombosis 20100630

Angiotensin II type 1 receptor blockers prevent tumor necrosis factor-alpha-mediated endothelial nitric oxide synthase reduction and superoxide production in human umbilical vein endothelial cells.

European journal of pharmacology 20100625

AT1 blockade attenuates atherosclerotic plaque destabilization accompanied by the suppression of cathepsin S activity in apoE-deficient mice.

Atherosclerosis 20100601

Economic evaluation of four angiotensin II receptor blockers in the treatment of hypertension.

Current medical research and opinion 20100601

Development and validation of a discriminating in vitro dissolution method for a poorly soluble drug, olmesartan medoxomil: comparison between commercial tablets.

AAPS PharmSciTech 20100601

A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension.

Hypertension (Dallas, Tex. : 1979) 20100601

Beating the clock: reducing cardiovascular risk by rapid blood pressure reduction with olmesartan.

Expert opinion on pharmacotherapy 20100601

Prevention of microalbuminuria in patients with type 2 diabetes: what do we know?

Journal of clinical hypertension (Greenwich, Conn.) 20100601

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20100601

Cardiac-specific activation of angiotensin II type 1 receptor-associated protein completely suppresses cardiac hypertrophy in chronic angiotensin II-infused mice.

Hypertension (Dallas, Tex. : 1979) 20100501

The angiotensin II type 1 receptor antagonist olmesartan preserves cerebral blood flow and cerebrovascular reserve capacity, and accelerates rehabilitative outcomes in hypertensive patients with a history of stroke.

The International journal of neuroscience 20100501

Olmesartan, an angiotensin II receptor blocker, restores cerebral hypoperfusion in elderly patients with hypertension.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 20100501

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20100501

Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.

Clinical therapeutics 20100501

Human carboxymethylenebutenolidase as a bioactivating hydrolase of olmesartan medoxomil in liver and intestine.

The Journal of biological chemistry 20100416

ANG II receptor blockade enhances anti-inflammatory macrophages in anti-glomerular basement membrane glomerulonephritis.

American journal of physiology. Renal physiology 20100401

Combination therapy with olmesartan and azelnidipine improves EDHF-mediated responses in diabetic apolipoprotein E-deficient mice.

Circulation journal : official journal of the Japanese Circulation Society 20100401

Loss of ACE2 accelerates time-dependent glomerular and tubulointerstitial damage in streptozotocin-induced diabetic mice.

Hypertension research : official journal of the Japanese Society of Hypertension 20100401

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20100401

Effect of olmesartan and pravastatin on experimental cerebral aneurysms in rats.

Brain research 20100331

Simultaneous quantitative determination of olmesartan and hydrochlorothiazide in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100315

Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial.

Journal of the American College of Cardiology 20100309

Plaque burden with composition? That is the next question.

Journal of the American College of Cardiology 20100309

Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension--results from the EUTOPIA trial.

Atherosclerosis 20100301

Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes.

Current medical research and opinion 20100301

Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans.

Journal of hypertension 20100301

Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters.

Biopharmaceutics & drug disposition 20100301

RP-HPLC-DAD method for determination of olmesartan medoxomil in bulk and tablets exposed to forced conditions.

Acta pharmaceutica (Zagreb, Croatia) 20100301

Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.

Clinical therapeutics 20100301

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20100301

Efficacy of olmesartan and nifedipine on recurrent hypoxia-induced left ventricular remodeling in diabetic mice.

Life sciences 20100227

Angiotensin II receptor blocker attenuates PDGF-induced mesangial cell migration in a receptor-independent manner.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20100201

Effects of walnut consumption on endothelial function in type 2 diabetic subjects: a randomized controlled crossover trial.

Diabetes care 20100201

Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension.

Hypertension research : official journal of the Japanese Society of Hypertension 20100201

Evaluation of blockbuster drugs under the rule-of-five.

Die Pharmazie 20100201

Olmesartan medoxomil evaluated for safety and efficacy in Indian patients with essential hypertension: a real world observational postmarketing surveillance.

The Journal of the Association of Physicians of India 20100201

Use of multiattribute utility theory for formulary management in a health system.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20100115

Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.

Diabetologia 20100101

Effects of olmesartan on Apelin/APJ and Akt/endothelial nitric oxide synthase pathway in Dahl rats with end-stage heart failure.

Journal of cardiovascular pharmacology 20100101

Medicinal chemistry of drugs used in diabetic cardiomyopathy.

Current medicinal chemistry 20100101

Efficacy of an olmesartan medoxomil-based treatment algorithm in patients stratified by age, race, or sex.

Journal of clinical hypertension (Greenwich, Conn.) 20100101

Cardioprotective effects of angiotensin II type 1 receptor blockade with olmesartan on reperfusion injury in a rat myocardial ischemia-reperfusion model.

Cardiovascular therapeutics 20100101

Doing what comes naturally.

Journal of general internal medicine 20100101

Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data.

American journal of cardiovascular drugs : drugs, devices, and other interventions 20100101

Renoprotective effect of calcium channel blockers in combination with an angiotensin receptor blocker in elderly patients with hypertension. A randomized crossover trial between benidipine and amlodipine.

Clinical and experimental hypertension (New York, N.Y. : 1993) 20100101

Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients.

Advances in therapy 20100101

Clinical and pharmacotherapeutic relevance of the double-chain domain of the angiotensin II type 1 receptor blocker olmesartan.

Clinical and experimental hypertension (New York, N.Y. : 1993) 20100101

Cyanobacterial cyclopeptides as lead compounds to novel targeted cancer drugs.

Marine drugs 20100101

New standards in hypertension and cardiovascular risk management: focus on telmisartan.

Vascular health and risk management 20100101

Development of a cell-based high-throughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3.

Current chemical genomics 20100101

Effects of telmisartan vs olmesartan on metabolic parameters, insulin resistance and adipocytokines in hypertensive obese patients.

Nutricion hospitalaria 20100101

Olmesartan inhibits angiotensin II-Induced migration of vascular smooth muscle cells through Src and mitogen-activated protein kinase pathways.

Journal of pharmacological sciences 20100101

Safety and tolerability of an olmesartan medoxomil-based regimen in patients with stage 1 hypertension: a randomized, double-blind, placebo-controlled study.

Clinical drug investigation 20100101

Use of evidence-based pharmacotherapy after myocardial infarction in Estonia.

BMC public health 20100101

Spectrophotometric estimation of olmesartan medoxomil and hydrochlorothiazide in tablet.

Indian journal of pharmaceutical sciences 20100101

Efficacy and safety of olmesartan medoxomil 40 mg/hydrochlorothiazide 12.5 mg combination therapy versus olmesartan medoxomil 40 mg monotherapy in patients with moderate to severe hypertension: a randomized, double-blind, parallel-group, multicentre, multinational, phase III study.

Clinical drug investigation 20100101

Involvement of TAGE-RAGE System in the Pathogenesis of Diabetic Retinopathy.

Journal of ophthalmology 20100101

Rhizoma Coptidis inhibits LPS-induced MCP-1/CCL2 production in murine macrophages via an AP-1 and NFkappaB-dependent pathway.

Mediators of inflammation 20100101

Effect of an olmesartan medoxomil-based treatment algorithm on systolic blood pressure in patients with stage 1 or 2 hypertension: a randomized, double-blind, placebo-controlled study.

American journal of cardiovascular drugs : drugs, devices, and other interventions 20100101

Impact of medical therapy on atheroma volume measured by different cardiovascular imaging modalities.

Cardiology research and practice 20100101

An olmesartan medoxomil-based treatment algorithm is effective in achieving 24-hour BP control in patients with type 2 diabetes mellitus, regardless of age, race, sex, or severity of hypertension: subgroup analysis of the BENIFICIARY study.

American journal of cardiovascular drugs : drugs, devices, and other interventions 20100101

Advanced glycation end products, oxidative stress and diabetic nephropathy.

Oxidative medicine and cellular longevity 20100101

Do we need more than just powerful blood pressure reductions? New paradigms in end-organ protection.

Vascular health and risk management 20100101

The bedtime administration ameliorates blood pressure variability and reduces urinary albumin excretion in amlodipine-olmesartan combination therapy.

Clinical and experimental hypertension (New York, N.Y. : 1993) 20100101

Role of olmesartan in combination therapy in blood pressure control and vascular function.

Vascular health and risk management 20100101

Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practice.

Vascular health and risk management 20100101

Olmesartan associated with acute renal failure in a patient with bilateral renal artery stenosis.

Renal failure 20100101

Renal protection in diabetes: lessons from ONTARGET.

Cardiovascular diabetology 20100101

Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma.

BMC cancer 20100101

Acute hepatocellular and cholestatic injury during therapy with hydrochlorothiazide - clinicohistopathologic findings: a case report.

Journal of medical case reports 20100101

Aging impairs myocardium-induced dilation in coronary arterioles: role of hydrogen peroxide and angiotensin.

Mechanisms of ageing and development 20100101

Complete disruption of all nitric oxide synthase genes causes markedly accelerated renal lesion formation following unilateral ureteral obstruction in mice in vivo.

Journal of pharmacological sciences 20100101

Attenuation of salt-induced cardiac remodeling and diastolic dysfunction by the GPER agonist G-1 in female mRen2.Lewis rats.

PloS one 20100101

Efficacy of combination therapy with telmisartan plus amlodipine in patients with poorly controlled hypertension.

Oxidative medicine and cellular longevity 20100101

Cardio classics revisited--focus on the role of candesartan.

Vascular health and risk management 20100101

Pilot study: rapidly cycling hypobaric pressure improves pain after 5 days in adiposis dolorosa.

Journal of pain research 20100101

Effects of angiotensin receptor blocker and calcium channel blocker on experimental abdominal aortic aneurysms in a hamster model.

The Kurume medical journal 20100101

Update on the role of candesartan in the optimal management of hypertension and cardiovascular risk reduction.

Integrated blood pressure control 20100101

Critical appraisal of the differential effects of antihypertensive agents on arterial stiffness.

Integrated blood pressure control 20100101

Impact of telmisartan in modifying vascular risk.

Integrated blood pressure control 20100101

Critical appraisal of amlodipine and olmesartan medoxomil fixed-dose combination in achieving blood pressure goals.

Integrated blood pressure control 20100101

Impact of olmesartan on blood pressure, endothelial function, and cardiovascular outcomes.

Integrated blood pressure control 20100101

Safety and tolerability of fixed antihypertensive combinations in blood pressure control: focus on olmesartan medoxomil and amlodipine combination.

Integrated blood pressure control 20100101

Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects.

Fundamental & clinical pharmacology 20091201

Olmesartan reduces oxidative stress in the brain of stroke-prone spontaneously hypertensive rats assessed by an in vivo ESR method.

Hypertension research : official journal of the Japanese Society of Hypertension 20091201

Angiotensin II and hypertonicity modulate proximal tubular aquaporin 1 expression.

American journal of physiology. Renal physiology 20091201

Angiotensin receptor blocker prevented beta-amyloid-induced cognitive impairment associated with recovery of neurovascular coupling.

Hypertension (Dallas, Tex. : 1979) 20091201

A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: the REZALT study.

Hypertension research : official journal of the Japanese Society of Hypertension 20091201

Ratio spectra derivative and zero-crossing difference spectrophotometric determination of olmesartan medoxomil and hydrochlorothiazide in combined pharmaceutical dosage form.

AAPS PharmSciTech 20091201

Effect of the angiotensin II type 1 receptor antagonist olmesartan on cerebral hemodynamics and rehabilitation outcomes in hypertensive post-stroke patients.

Brain injury 20091201

Evaluation for antioxidant and renoprotective activity of olmesartan using nephrectomy rats.

Biological & pharmaceutical bulletin 20091201

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20091201

Mmp-9, a potential target for cerebral ischemic treatment.

Current neuropharmacology 20091201

Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.

Hypertension research : official journal of the Japanese Society of Hypertension 20091101

Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication use.

Journal of cardiovascular pharmacology 20091101

Benefits of the angiotensin II receptor antagonist olmesartan in controlling hypertension and cerebral hemodynamics after stroke.

Hypertension research : official journal of the Japanese Society of Hypertension 20091101

Effects of angiotensin II receptor blockers on the relationships between ambulatory blood pressure and anti-hypertensive effects, autonomic function, and health-related quality of life.

Clinical and experimental hypertension (New York, N.Y. : 1993) 20091101

Solubilized formulation of olmesartan medoxomil for enhancing oral bioavailability.

Archives of pharmacal research 20091101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20091101

Olmesartan medoxomil ameliorates sciatic nerve regeneration in diabetic rats.

Neuroreport 20091028

A sartan derivative with a very low angiotensin II receptor affinity ameliorates ischemic cerebral damage.

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20091001

Multivalent ligand-receptor interactions elicit inverse agonist activity of AT(1) receptor blockers against stretch-induced AT(1) receptor activation.

Hypertension research : official journal of the Japanese Society of Hypertension 20091001

Significance of angiotensin II receptor blockers with high affinity to angiotensin II type 1 receptors for vascular protection in rats.

Hypertension research : official journal of the Japanese Society of Hypertension 20091001

Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients.

Hypertension (Dallas, Tex. : 1979) 20091001

Central blood pressure under angiotensin and calcium channel blockade.

Hypertension (Dallas, Tex. : 1979) 20091001

Does treatment with olmesartan improve arterial stenoses due to fibromuscular dysplasia?

Hypertension research : official journal of the Japanese Society of Hypertension 20091001

Combination of chronic exercise and antihypertensive therapy enhances renoprotective effects in rats with renal ablation.

American journal of hypertension 20091001

Estimating antihypertensive effects of combination therapy in an observational study using marginal structural models.

Biometrical journal. Biometrische Zeitschrift 20091001

[New developments in glaucoma medical treatment].

Archivos de la Sociedad Espanola de Oftalmologia 20091001

Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension.

Journal of atherosclerosis and thrombosis 20091001

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20091001

Culture period-dependent change of function and expression of ATP-binding cassette transporters in Caco-2 cells.

Drug metabolism and disposition: the biological fate of chemicals 20090901

Re: Efficacy and safety of the single pill combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not controlled by amlodipine 10 mg plus olmesartan 20 mg in free combination.

Current medical research and opinion 20090901

Efficacy in angiotensin receptor blockade: a comparative review of data with olmesartan.

Journal of the renin-angiotensin-aldosterone system : JRAAS 20090901

Renoprotective effects of an angiotensin II receptor blocker in experimental model rats with hypertension and metabolic disorders.

Hypertension research : official journal of the Japanese Society of Hypertension 20090901

AT(1) receptor blockers increase insulin-like growth factor-I production by stimulating sensory neurons in spontaneously hypertensive rats.

Translational research : the journal of laboratory and clinical medicine 20090901

Olmesartan medoxomil: recent clinical and experimental acquisitions.

Expert opinion on drug metabolism & toxicology 20090901

Contribution of chymase-dependent angiotensin II formation to the progression of tubulointerstitial fibrosis in obstructed kidneys in hamsters.

Journal of pharmacological sciences 20090901

Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension.

Journal of clinical hypertension (Greenwich, Conn.) 20090901

Reversing bacteria-induced vitamin D receptor dysfunction is key to autoimmune disease.

Annals of the New York Academy of Sciences 20090901

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20090901

[Sevikar or Forzaten: olmesartan medoxomil and amlodipine besylate fixed combination in the treatment of hypertension].

Revue medicale de Liege 20090901

Role of activated intrarenal reactive oxygen species and renin-angiotensin system in IgA nephropathy model mice.

Clinical and experimental pharmacology & physiology 20090801

Guanylyl cyclase-A inhibits angiotensin II type 2 receptor-mediated pro-hypertrophic signaling in the heart.

Endocrinology 20090801

Circulating angiopoietin-2 in essential hypertension: relation to atherosclerosis, vascular inflammation, and treatment with olmesartan/pravastatin.

Journal of hypertension 20090801

Reduction in urinary excretion of neutrophil gelatinase-associated lipocalin by angiotensin receptor blockers in hypertensive patients.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20090801

The involvement of aldosterone in cyclic stretch-mediated activation of NADPH oxidase in vascular smooth muscle cells.

Hypertension research : official journal of the Japanese Society of Hypertension 20090801

Improvement of glucose intolerance by combination of pravastatin and olmesartan in type II diabetic KK-A(y) mice.

Hypertension research : official journal of the Japanese Society of Hypertension 20090801

Renal and vascular glutathione S-transferase mu is not affected by pharmacological intervention to reduce systolic blood pressure.

Journal of hypertension 20090801

Direct action of an angiotensin II receptor blocker on angiotensin II-induced left atrial conduction delay in spontaneously hypertensive rats.

Hypertension research : official journal of the Japanese Society of Hypertension 20090801

Comparison of olmesartan medoxomil versus amlodipine besylate on regression of ventricular and vascular hypertrophy.

The American journal of cardiology 20090801

Treatment of hypertension in metabolic syndrome subjects with amlodipine and olmesartan-effects on oxidized non-esterified free fatty acids and cytokine production.

Cardiovascular drugs and therapy 20090801

Amlodipine besylate/olmesartan medoximil fixed combination for the treatment of hypertension.

Expert review of cardiovascular therapy 20090801

The effects of an olmesartan medoxomil-based treatment algorithm on 24-hour blood pressure levels in elderly patients aged 65 and older.

Journal of clinical hypertension (Greenwich, Conn.) 20090801

24-hour and nighttime blood pressures in type 2 diabetic hypertensive patients following morning or evening administration of olmesartan.

Journal of clinical hypertension (Greenwich, Conn.) 20090801

Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).

Hypertension research : official journal of the Japanese Society of Hypertension 20090701

Effects of combined olmesartan and pravastatin on glucose intolerance and cardiovascular remodeling in a metabolic-syndrome model.

Hypertension research : official journal of the Japanese Society of Hypertension 20090701

Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation.

Hypertension research : official journal of the Japanese Society of Hypertension 20090701

Mechanism of diastolic stiffening of the failing myocardium and its prevention by angiotensin receptor and calcium channel blockers.

Journal of cardiovascular pharmacology 20090701

Olmesartan ameliorates myocardial function independent of blood pressure control in patients with mild-to-moderate hypertension.

Heart and vessels 20090701

Study of the acute cardiovascular effects of several antihypertensive agents with the measurement of plasma catecholamines in mice.

Analytical and bioanalytical chemistry 20090601

Diabetes mellitus accelerates left ventricular diastolic dysfunction through activation of the renin-angiotensin system in hypertensive rats.

Hypertension research : official journal of the Japanese Society of Hypertension 20090601

Blockade of angiotensin II type-1 receptor increases salt sensitivity in Sprague-Dawley rats.

Hypertension research : official journal of the Japanese Society of Hypertension 20090601

Did Dr. & nurse fail notify pregnant Pt. to D/C Benicar? Mobile OB-GYN, PC. v. Baggett, 2009-AL-0615.006 (6/12/2009)-AL.

Nursing law's Regan report 20090601

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20090601

Angiotensin II type 1 receptor blocker attenuates the activation of ERK and NADPH oxidase by mechanical strain in mesangial cells in the absence of angiotensin II.

American journal of physiology. Renal physiology 20090501

Effects of angiotensin II receptor blockers on relationships between 24-hour blood pressure, autonomic function, and health-related QOL.

Clinical and experimental hypertension (New York, N.Y. : 1993) 20090501

Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach.

International journal of clinical practice 20090501

Favorable cardiac and aortic remodeling in olmesartan-treated spontaneously hypertensive rats.

Heart and vessels 20090501

Pharmacokinetic and safety profile of olmesartan medoxomil in healthy Chinese subjects after single and multiple administrations.

Die Pharmazie 20090501

Olmesartan clinical trial in Okinawan patients under OKIDS (OCTOPUS) study: design and methods.

Clinical and experimental nephrology 20090401

Olmesartan improves left ventricular function in pressure-overload hypertrophied rat heart by blocking angiotensin II receptor with synergic effects of upregulation of angiotensin converting enzyme 2.

Therapeutic advances in cardiovascular disease 20090401

Influence of guidelines on physicians' assessment of blood pressure lowering effects and achievement rate of blood pressure target during transitional period of guidelines.

Clinical and experimental hypertension (New York, N.Y. : 1993) 20090401

Blood pressure-lowering effects of angiotensin receptor antagonist monotherapy and in combination with other anti-hypertensive drugs in primary care settings in Japan.

Clinical and experimental hypertension (New York, N.Y. : 1993) 20090401

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20090401

Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors.

Drug metabolism and disposition: the biological fate of chemicals 20090301

Angiotensin II reduces mitochondrial content in skeletal muscle and affects glycemic control.

Diabetes 20090301

Efficacy and safety of olmesartan medoxomil alone and in combination with hydrochlorothiazide.

Expert review of cardiovascular therapy 20090301

Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: an emerging strategy in hypertension therapy.

Postgraduate medicine 20090301

Complementary mechanisms of angiotensin receptor blockers and calcium channel blockers in managing hypertension.

Postgraduate medicine 20090301

Activated intrarenal reactive oxygen species and renin angiotensin system in IgA nephropathy.

Minerva urologica e nefrologica = The Italian journal of urology and nephrology 20090301

Pharmacokinetics of olmesartan medoxomil in hemodialysis patients: little effect of dialysis upon its pharmacokinetics.

Clinical and experimental nephrology 20090201

Continuous activation of renin-angiotensin system impairs cognitive function in renin/angiotensinogen transgenic mice.

Hypertension (Dallas, Tex. : 1979) 20090201

Prevention of vascular injury by combination of an AT1 receptor blocker, olmesartan, with various calcium antagonists.

American journal of hypertension 20090201

Angiotensin II receptor blockade inhibits acute glomerular injuries with the alteration of receptor expression.

Laboratory investigation; a journal of technical methods and pathology 20090201

Efficacy and safety of the single pill combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not controlled by amlodipine 10 mg plus olmesartan 20 mg in free combination.

Current medical research and opinion 20090201

Olmesartan and temocapril prevented the development of hyperglycemia and the deterioration of pancreatic islet morphology in Otsuka-Long-Evans-Tokushima Fatty rats.

Acta medica Okayama 20090201

Rationale, study design and implementation of the COLM study: the combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients.

Hypertension research : official journal of the Japanese Society of Hypertension 20090201

Effects of angiotensin II type 1 receptor blocker on albumin-induced cell damage in human renal proximal tubular epithelial cells.

American journal of nephrology 20090101

Relationship between silent brain infarction and chronic kidney disease.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20090101

Angiotensin II type 1 receptor antagonists prevent glucose-induced increases in islet blood flow in rats.

Scandinavian journal of clinical and laboratory investigation 20090101

Regulation of coronary vascular tone via redox modulation in the alpha1-adrenergic-angiotensin-endothelin axis of the myocardium.

American journal of physiology. Heart and circulatory physiology 20090101

Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes.

Diabetes research and clinical practice 20090101

Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study.

Clinical drug investigation 20090101

Olmesartan medoxomil in elderly patients with essential or isolated systolic hypertension : efficacy and safety data from clinical trials.

Drugs & aging 20090101

Olmesartan/Amlodipine: combination therapy for the treatment of hypertension [corrected].

Advances in therapy 20090101

Administration-time-dependent effects of olmesartan on the ambulatory blood pressure of essential hypertension patients.

Chronobiology international 20090101

Cardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis.

American journal of cardiovascular drugs : drugs, devices, and other interventions 20090101

Antihypertensive efficacy of olmesartan medoxomil or valsartan in combination with amlodipine: a review of factorial-design studies.

Current medical research and opinion 20090101

ACE inhibition attenuates uremia-induced aortic valve thickening in a novel mouse model.

BMC cardiovascular disorders 20090101

Relationship between decrease in ambulatory blood pressure and heart rate variability due to the effects of taking olmesartan medoxomil.

Clinical drug investigation 20090101

Analysis of published economic evaluations of angiotensin receptor blockers.

Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese 20090101

Down-regulation of hepatic stearoyl-CoA desaturase 1 expression by angiotensin II receptor blocker in the obese fa/fa Zucker rat: possible role in amelioration of insulin resistance and hepatic steatosis.

Journal of gastroenterology 20090101

Antiproteinuric effect of olmesartan in patients with IgA nephropathy.

Journal of nephrology 20090101

The roles of ASK family proteins in stress responses and diseases.

Cell communication and signaling : CCS 20090101

Olmesartan medoxomil/amlodipine.

Drugs 20090101

Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study.

Clinical drug investigation 20090101

Effective systolic blood pressure reduction with olmesartan medoxomil/amlodipine combination therapy: post hoc analysis of data from a randomized, double-blind, parallel-group, multicentre study.

Clinical drug investigation 20090101

Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil.

Vascular health and risk management 20090101

Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension.

Vascular health and risk management 20090101

The effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in man.

Vascular health and risk management 20090101

Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study.

Vascular health and risk management 20090101

Comparative effects of olmesartan and azelnidipine on atrial structural remodeling in spontaneously hypertensive rats.

Pharmacology 20090101

Role of angiotensin II type 1 receptor on retinal vascular leakage in a rat oxygen-induced retinopathy model.

Ophthalmic research 20090101

Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre study.

Clinical drug investigation 20090101

Effect of olmesartan medoxomil on cystatin C level, left ventricular hypertrophy and diastolic function.

Blood pressure 20090101

Effects of new peritoneal dialysis solutions, pyridoxamine and AT1 receptor blocker, on TGF-beta1 and VEGF expression in rat peritoneal mesothelial cells.

American journal of nephrology 20090101

[Case of Henoch-Schönlein purpura nephritis successfully treated with tonsillectomy and steroid pulse therapy].

Nihon Jinzo Gakkai shi 20090101

Angiotensin II Type 1 Receptor Blockers Reduce Urinary Angiotensinogen Excretion and the Levels of Urinary Markers of Oxidative Stress and Inflammation in Patients with Type 2 Diabetic Nephropathy.

Biomarker insights 20090101

Combination therapy with olmesartan medoxomil and hydrochlorothiazide: secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study.

American journal of cardiovascular drugs : drugs, devices, and other interventions 20090101

Angiotensins and Alzheimer's disease: a bench to bedside overview.

Alzheimer's research & therapy 20090101

Comparative pharmacodynamics of olmesartan and azelnidipine in patients with hypertension: a population pharmacokinetic/pharmacodynamic analysis.

Drug metabolism and pharmacokinetics 20090101

Beneficial effects of combination therapy with olmesartan and azelnidipine in murine polycystic kidneys.

Kidney & blood pressure research 20090101

Blood pressure goal achievement with olmesartan medoxomil-based treatment: additional analysis of the OLMEBEST study.

Vascular health and risk management 20090101

Angiotensin II receptor blockers in the prevention of complications from atrial fibrillation.

Vascular health and risk management 20090101

Drugs associated with more suicidal ideations are also associated with more suicide attempts.

PloS one 20090101

Vancomycin-induced thrombocytopenia in a 60-year-old man: a case report.

Journal of medical case reports 20090101

Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension.

Respiratory research 20090101

An evaluation of the efficacy of olmesartan medoxomil in Black patients with hypertension.

Journal of the American Society of Hypertension : JASH 20090101

Derivative and Q-analysis Spectrophotometric Methods for Estimation of Hydrochlorothiazide and Olmesartan Medoxomil in Tablets.

Indian journal of pharmaceutical sciences 20090101

Simultaneous estimation of amlodipine besilate and olmesartan medoxomil in pharmaceutical dosage form.

Indian journal of pharmaceutical sciences 20090101

Combination therapy based on the angiotensin receptor blocker olmesartan for vascular protection in spontaneously hypertensive rats.

Molecular medicine reports 20090101

Effects of antihypertensive drugs on carotid intima-media thickness: Focus on angiotensin II receptor blockers. A review of randomized, controlled trials.

Integrated blood pressure control 20090101

Valsartan combination therapy in the management of hypertension - patient perspectives and clinical utility.

Integrated blood pressure control 20090101

Current concepts in combination therapy for the treatment of hypertension: combined calcium channel blockers and RAAS inhibitors.

Integrated blood pressure control 20090101

Reduction of albuminuria by angiotensin receptor blocker beyond blood pressure lowering: evaluation in megsin/receptor for advanced glycation end products/inducible nitric oxide synthase triple transgenic diabetic nephropathy mouse model.

Nephrology (Carlton, Vic.) 20081201

Enhanced pulsatile pressure accelerates vascular smooth muscle migration: implications for atherogenesis of hypertension.

Cardiovascular research 20081201

Mast cells and epsilonPKC: a role in cardiac remodeling in hypertension-induced heart failure.

Journal of molecular and cellular cardiology 20081201

Targeting the angiotensin pathway in idiopathic pulmonary fibrosis.

Expert opinion on therapeutic targets 20081201

Results of an olmesartan medoxomil-based treatment regimen in hypertensive patients.

Journal of clinical hypertension (Greenwich, Conn.) 20081201

Early antihypertensive efficacy of olmesartan medoxomil.

Journal of clinical hypertension (Greenwich, Conn.) 20081201

Angiotensin type 1 receptor blockade prevents cardiac remodeling in mice with pregnancy-associated hypertension.

Hypertension research : official journal of the Japanese Society of Hypertension 20081201

Clinical efficacy and safety of olmesartan/hydrochlorothiazide combination therapy in patients with essential hypertension.

Vascular health and risk management 20081201

The evolution of systolic blood pressure as a strong predictor of cardiovascular risk and the effectiveness of fixed-dose ARB/CCB combinations in lowering levels of this preferential target.

Vascular health and risk management 20081201

Evaluation of role of angiotensin III and aminopeptidases in prostate cancer cells.

The Prostate 20081101

MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides.

American journal of physiology. Cell physiology 20081101

Intrarenal RAS activity and urinary angiotensinogen excretion in anti-thymocyte serum nephritis rats.

American journal of physiology. Renal physiology 20081101

Pharmacokinetics of amlodipine and olmesartan after administration of amlodipine besylate and olmesartan medoxomil in separate dosage forms and as a fixed-dose combination.

Journal of clinical pharmacology 20081101

Endothelial progenitor cells dysfunction and senescence: contribution to oxidative stress.

Current cardiology reviews 20081101

A novel Sartan derivative with very low angiotensin II type 1 receptor affinity protects the kidney in type 2 diabetic rats.

Arteriosclerosis, thrombosis, and vascular biology 20081001

Allopurinol attenuates L-NAME induced cardiomyopathy comparable to blockade of angiotensin receptor.

Histology and histopathology 20081001

Effect of olmesartan on tissue expression balance between angiotensin II receptor and its inhibitory binding molecule.

Hypertension (Dallas, Tex. : 1979) 20081001

Therapeutic effect of ARBs on insulin resistance and liver injury in patients with NAFLD and chronic hepatitis C: a pilot study.

International journal of molecular medicine 20081001

Successful treatment of post-MRSA infection glomerulonephritis with steroid therapy.

Clinical nephrology 20081001

Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use.

Diabetic medicine : a journal of the British Diabetic Association 20081001

In vitro biliary clearance of angiotensin II receptor blockers and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in sandwich-cultured rat hepatocytes: comparison with in vivo biliary clearance.

The Journal of pharmacology and experimental therapeutics 20080901

Intrarenal angiotensin II and angiotensinogen augmentation in chronic angiotensin II-infused mice.

American journal of physiology. Renal physiology 20080901

Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition.

Hypertension (Dallas, Tex. : 1979) 20080901

Based treatment algorithm for essencial hypertension with olmesartan medoxomil.

Arquivos brasileiros de cardiologia 20080901

Simultaneous determination of olmesartan medoxomil and irbesartan and hydrochlorothiazide in pharmaceutical formulations and human serum using high performance liquid chromatography.

Se pu = Chinese journal of chromatography 20080901

Modifications by Olmesartan medoxomil treatment of the platelet protein profile of moderate hypertensive patients.

Proteomics. Clinical applications 20080901

Superoxide-dependent cathepsin activation is associated with hypertensive myocardial remodeling and represents a target for angiotensin II type 1 receptor blocker treatment.

The American journal of pathology 20080801

Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients.

Current medical research and opinion 20080801

Angiotensin receptor blockers improve insulin signaling and prevent microvascular rarefaction in the skeletal muscle of spontaneously hypertensive rats.

Journal of hypertension 20080801

Identification of a degradation product in stressed tablets of olmesartan medoxomil by the complementary use of HPLC hyphenated techniques.

Journal of pharmaceutical and biomedical analysis 20080715

Olmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis through its pleiotropic effects.

European journal of pharmacology 20080707

Angiotensin II accelerates osteoporosis by activating osteoclasts.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20080701

Costimulation with angiotensin II and interleukin 6 augments angiotensinogen expression in cultured human renal proximal tubular cells.

American journal of physiology. Renal physiology 20080701

Evaluation of population pharmacokinetics and exposure-response relationship with coadministration of amlodipine besylate and olmesartan medoxomil.

Journal of clinical pharmacology 20080701

Quality of life in hypertension management using olmesartan in primary care.

Expert opinion on pharmacotherapy 20080701

Cost-utility analysis of antihypertensive combination therapy in Japan by a Monte Carlo simulation model.

Hypertension research : official journal of the Japanese Society of Hypertension 20080701

Olmesartan for the treatment of arterial hypertension.

Future cardiology 20080701

[Effects of angiotensin II type 1 receptor blocker on triglyceride metabolism in the liver: experiment with Zucker fatty rats].

Zhonghua yi xue za zhi 20080610

Angiotensin (1-7) reduces intraocular pressure in the normotensive rabbit eye.

Investigative ophthalmology & visual science 20080601

Urinary Smad1 is a novel marker to predict later onset of mesangial matrix expansion in diabetic nephropathy.

Diabetes 20080601

Angiotensin II receptor blocker inhibits tumour necrosis factor-alpha-induced cell damage in human renal proximal tubular epithelial cells.

Nephrology (Carlton, Vic.) 20080601

Angiotensin II receptor antagonism reverts the selective cardiac BNP upregulation and secretion observed in myocarditis.

American journal of physiology. Heart and circulatory physiology 20080601

Pharmacological inhibition of epsilon-protein kinase C attenuates cardiac fibrosis and dysfunction in hypertension-induced heart failure.

Hypertension (Dallas, Tex. : 1979) 20080601

The collecting duct is the major source of prorenin in diabetes.

Hypertension (Dallas, Tex. : 1979) 20080601

Role of the renin-angiotensin system in the pathogenesis of peritoneal fibrosis.

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 20080601

[High-performance liquid chromatography-mass spectrometry for determining olmesartan in human plasma].

Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20080601

Amlodipine/ARB fixed-dose combinations for the treatment of hypertension: focus on amlodipine/olmesartan combination.

Drugs of today (Barcelona, Spain : 1998) 20080601

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20080601

Fixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of the olmesartan-amlodipine combination.

Vascular health and risk management 20080601

Mitochondrial dysfunction and redox signaling in atrial tachyarrhythmia.

Experimental biology and medicine (Maywood, N.J.) 20080501

[Lowering blood pressure and more? AT1 antagonist reduced plaque volume].

MMW Fortschritte der Medizin 20080501

Comparison of the effects of telmisartan and olmesartan on home blood pressure, glucose, and lipid profiles in patients with hypertension, chronic heart failure, and metabolic syndrome.

Hypertension research : official journal of the Japanese Society of Hypertension 20080501

The use of olmesartan medoxomil as monotherapy or in combination with other antihypertensive agents in elderly hypertensive patients in Japan.

Journal of clinical hypertension (Greenwich, Conn.) 20080401

The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study.

Clinical therapeutics 20080401

Cellular physiology of rat cardiac myocytes in cardiac fibrosis: in vitro simulation using the cardiac myocyte/cardiac non-myocyte co-culture system.

Hypertension research : official journal of the Japanese Society of Hypertension 20080401

Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers.

Pharmaceutical research 20080301

Oxidative stress in mononuclear cells plays a dominant role in their adhesion to mouse femoral artery after injury.

Hypertension (Dallas, Tex. : 1979) 20080301

Angiotensin II type 1 receptor blocker, olmesartan, restores nocturnal blood pressure decline by enhancing daytime natriuresis.

Journal of hypertension 20080301

Unusual detritylation of tritylated tetrazole in Sartan molecules.

Chemical & pharmaceutical bulletin 20080301

Effects of antihypertensive drugs and exercise training on insulin sensitivity in spontaneously hypertensive rats.

Hypertension research : official journal of the Japanese Society of Hypertension 20080301

Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockade.

Hypertension research : official journal of the Japanese Society of Hypertension 20080301

Angiotensin II receptor blockade reduces tachycardia-induced atrial adhesion molecule expression.

Circulation 20080212

Matrix metalloproteinase gene delivery for liver fibrosis.

Pharmaceutical research 20080201

Reversible acute fetal renal failure due to maternal exposure to angiotensin receptor blocker.

Pediatric nephrology (Berlin, Germany) 20080201

Olmesartan ameliorates progressive glomerular injury in subtotal nephrectomized rats through suppression of superoxide production.

Hypertension research : official journal of the Japanese Society of Hypertension 20080201

Endothelial effects of antihypertensive treatment: focus on irbesartan.

Vascular health and risk management 20080201

Chronic heart failure in Japan: implications of the CHART studies.

Vascular health and risk management 20080201

Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression.

Microvascular research 20080101

Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state.

Molecular endocrinology (Baltimore, Md.) 20080101

Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species.

Ophthalmic research 20080101

Olmesartan medoxomil plus hydrochlorothiazide for treating hypertension.

Expert opinion on pharmacotherapy 20080101

Estrogen and angiotensin II interactions determine cardio-renal damage in Dahl salt-sensitive rats with heart failure.

American journal of nephrology 20080101

Evaluation of olmesartan medoxomil in the rat monocrotaline model of pulmonary hypertension.

Journal of cardiovascular pharmacology 20080101

Effect of delapril/manidipine vs olmesartan/ hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients.

Internal medicine (Tokyo, Japan) 20080101

Mechanical stretch induced interleukin-18 (IL-18) expression through Angiotensin subtype 1 receptor (AT1R) and endothelin-1 in cardiomyocytes.

Preparative biochemistry & biotechnology 20080101

Possible beneficial effect of olmesartan medoxomil on left atrial function in patients with hypertension : noninvasive assessment by acoustic quantification.

Clinical drug investigation 20080101

Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension.

Hypertension research : official journal of the Japanese Society of Hypertension 20080101

Effects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitus.

Hypertension research : official journal of the Japanese Society of Hypertension 20080101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20080101

Improvement of stunned myocardium in dogs with olmesartan, an angiotensin II type 1 receptor antagonist, is independent of type 2 receptors.

Pharmacology 20080101

Angiotensin II type 2 receptor antagonist reduces bleomycin-induced pulmonary fibrosis in mice.

Respiratory research 20080101

PPARgamma Agonists: Potential as Therapeutics for Neovascular Retinopathies.

PPAR research 20080101

Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension.

Drugs 20080101

Olmesartan medoxomil: a review of its use in the management of hypertension.

Drugs 20080101

Pseudoaldosteronism caused by combined administration of cilostazol and glycyrrhizin.

Internal medicine (Tokyo, Japan) 20080101

Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism.

Journal of human genetics 20080101

Takotsubo cardiomyopathy associated with anesthesia: three case reports.

Cases journal 20080101

The prince and the pauper. A tale of anticancer targeted agents.

Molecular cancer 20080101

Young carers in Germany: to live on as normal as possible - a grounded theory study.

BMC nursing 20080101

Severe neonatal renal failure after maternal use of angiotensin II type I receptor antagonists.

La Pediatria medica e chirurgica : Medical and surgical pediatrics 20080101

Reversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II receptors.

Journal of the American Society of Hypertension : JASH 20080101

Two amlodipine/ARB combinations for hypertension.

The Medical letter on drugs and therapeutics 20071217

New angiotensin II type 1 receptor blocker olmesartan improves portal hypertension in patients with cirrhosis.

Hepatology research : the official journal of the Japan Society of Hepatology 20071201

Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.

Drug metabolism and disposition: the biological fate of chemicals 20071201

Maximising antihypertensive effects of angiotensin II receptor blockers with thiazide diuretic combination therapy: focus on irbesartan/hydrochlorothiazide.

International journal of clinical practice 20071201

Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3Leiden transgenic mice.

Journal of hypertension 20071201

Inhibition of cognitive decline in mice fed a high-salt and cholesterol diet by the angiotensin receptor blocker, olmesartan.

Neuropharmacology 20071201

Reverse-remodeling effects of angiotensin II type 1 receptor blocker in a canine atrial fibrillation model.

Circulation journal : official journal of the Japanese Circulation Society 20071201

Angiotensin II receptor blocker reduces oxidative stress and attenuates hypoxia-induced left ventricular remodeling in apolipoprotein E-knockout mice.

Hypertension research : official journal of the Japanese Society of Hypertension 20071201

Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study.

Therapeutic advances in cardiovascular disease 20071201

Expression of inhibitor of apoptosis protein Livin in renal cell carcinoma and non-tumorous adult kidney.

British journal of cancer 20071105

Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy.

American journal of hypertension 20071101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20071101

Angiotensin II provokes podocyte injury in murine model of HIV-associated nephropathy.

American journal of physiology. Renal physiology 20071001

Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension.

Journal of hypertension 20071001

Olmesartan ameliorates renovascular injury and oxidative stress in Zucker obese rats enhanced by dietary protein.

American journal of hypertension 20071001

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20071001

Inhibition of balloon injury-induced neointimal formation by olmesartan and pravastatin in rats with insulin resistance.

Hypertension research : official journal of the Japanese Society of Hypertension 20071001

Aldosterone-and-salt-induced cardiac fibrosis is independent from angiotensin II type 1a receptor signaling in mice.

Hypertension research : official journal of the Japanese Society of Hypertension 20071001

Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients.

Journal of the American College of Cardiology 20070918

Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: an update.

Journal of human hypertension 20070901

Quantitative determination of olmesartan in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070901

An angiotensin II type-I receptor blocker, olmesartan medoxomil, attenuates lipid peroxidation in renal injury induced by subtotal nephrectomy.

Clinical and experimental nephrology 20070901

Angiotensin type 1 receptor blockade prevents endocardial dysfunction of rapidly paced atria in rats.

Journal of the renin-angiotensin-aldosterone system : JRAAS 20070901

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20070901

Do all angiotensin II type 1 receptor blockers have the same beneficial effects?

British journal of pharmacology 20070801

Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor.

British journal of pharmacology 20070801

Socio-economic status and the therapeutic effectiveness of antihypertensive treatment--the design of the LEO study.

Current medical research and opinion 20070801

Effects of angiotensin receptor blockers on ambulatory plasma Renin activity in healthy, normal subjects during unrestricted sodium intake.

American journal of hypertension 20070801

Inhibitory effects of angiotensin receptor blockers on CYP2C9 activity in human liver microsomes.

Drug metabolism and pharmacokinetics 20070801

Common pathways of hypercholesterolemia and hypertension leading to atherothrombosis: the need for a global approach in the management of cardiovascular risk factors.

Vascular health and risk management 20070801

Expression of the local angiotensin II system in gastric cancer may facilitate lymphatic invasion and nodal spread.

Cancer biology & therapy 20070801

Renin-angiotensin inhibition reverses advanced cardiac remodeling in aging spontaneously hypertensive rats.

American journal of hypertension 20070701

[Acute renal failure induced by angiotensin II receptor blocker in a patient with horseshoe kidney].

Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20070610

An angiotensin II receptor blocker increases sexual behavior in type 2 diabetic mice.

Physiology & behavior 20070608

Regulation of scavenger receptor class BI gene expression by angiotensin II in vascular endothelial cells.

Hypertension (Dallas, Tex. : 1979) 20070601

Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis.

Hepatology (Baltimore, Md.) 20070601

Determination of olmesartan medoxomil in tablets by UV-Vis spectrophotometry.

Die Pharmazie 20070601

[ARB: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].

Nihon rinsho. Japanese journal of clinical medicine 20070528

[Effect of olmesartan medoxomil on arterial stiffness in patients with essential hypertension].

Medicina clinica 20070519

Inhibition of Fas-associated apoptosis in granulation tissue cells accompanies attenuation of postinfarction left ventricular remodeling by olmesartan.

American journal of physiology. Heart and circulatory physiology 20070501

Effect of olmesartan on oxidative stress in hemodialysis patients.

Hypertension research : official journal of the Japanese Society of Hypertension 20070501

Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits.

Journal of the American College of Cardiology 20070403

Role of AT1 receptor in isoproterenol-induced cardiac hypertrophy and oxidative stress in mice.

Journal of molecular and cellular cardiology 20070401

Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies.

Fundamental & clinical pharmacology 20070401

[Partial androgen deficiency of the aging male and clinical response to conventional medical therapy in patients with metabolic syndrome].

Minerva medica 20070401

Role of angiotensin II type-1 and type-2 receptors on vascular smooth muscle cell growth and glucose metabolism in diabetic rats.

Diabetes research and clinical practice 20070301

Pravastatin enhances beneficial effects of olmesartan on vascular injury of salt-sensitive hypertensive rats, via pleiotropic effects.

Arteriosclerosis, thrombosis, and vascular biology 20070301

A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats.

The Journal of endocrinology 20070301

Manidipine plus delapril in patients with Type 2 diabetes and hypertension: reducing cardiovascular risk and end-organ damage.

Expert review of cardiovascular therapy 20070301

Olmesartan medoxomil-induced angioedema.

The Annals of pharmacotherapy 20070301

Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension.

Journal of clinical hypertension (Greenwich, Conn.) 20070301

[Medication of the month. Olmesartan medoxomil hydroclorothiazide (Olmetec Plus or Belsar Plus].

Revue medicale de Liege 20070301

Therapeutic effects of angiotensin II type 1 receptor blocker at an advanced stage of hypertensive diastolic heart failure.

Journal of hypertension 20070201

Angiotensin II type 1 receptor blockade inhibits the development and progression of HIV-associated nephropathy in a mouse model.

Journal of the American Society of Nephrology : JASN 20070201

Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter.

The Journal of pharmacology and experimental therapeutics 20070101

Angiotensin II receptor blockade ameliorates mesangioproliferative glomerulonephritis in rats through suppression of CTGF and PAI-1, independently of the coagulation system.

Nephron. Experimental nephrology 20070101

Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study.

Journal of clinical hypertension (Greenwich, Conn.) 20070101

Titration of HCTZ to 50 mg daily in individuals with stage 2 systolic hypertension pretreated with an angiotensin receptor blocker.

Journal of clinical hypertension (Greenwich, Conn.) 20070101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20070101

Comparison of the efficacy of morning versus evening administration of olmesartan in uncomplicated essential hypertension.

Chronobiology international 20070101

Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.

Clinical drug investigation 20070101

Angiotensin II antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial: rationale and study design.

Clinical drug investigation 20070101

Angiotensin II receptor blockers decreased blood glucose levels: a longitudinal survey using data from electronic medical records.

Cardiovascular diabetology 20070101

Updated meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure.

Clinical drug investigation 20070101

[Scuba diving -- a therapeutic option for patients with paraplegia].

Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater 20070101

Dose-response characteristics of olmesartan medoxomil and other angiotensin receptor antagonists.

American journal of cardiovascular drugs : drugs, devices, and other interventions 20070101

Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate.

American journal of cardiovascular drugs : drugs, devices, and other interventions 20070101

Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan.

The Journal of pharmacology and experimental therapeutics 20061201

Effects of olmesartan, an AT1 receptor antagonist, on hypoxia-induced activation of ERK1/2 and pro-inflammatory signals in the mouse lung.

Naunyn-Schmiedeberg's archives of pharmacology 20061201

Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: effects of angiotensin II blockade.

Journal of the American Society of Nephrology : JASN 20061201

Olmesartan medoxomil: current status of its use in monotherapy.

Vascular health and risk management 20061201

Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension.

Vascular health and risk management 20061201

Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation.

Kidney international 20061101

Synergistic protective effects of erythropoietin and olmesartan on ischemic stroke survival and post-stroke memory dysfunctions in the gerbil.

Journal of hypertension 20061101

Angiotensin II regulates migration in mouse cultured mesangial cells: evidence for the presence of receptor subtype-specific regulation.

The Journal of endocrinology 20061101

Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme.

Hypertension research : official journal of the Japanese Society of Hypertension 20061101

Letter by Krop et al regarding article, 'Role of p90 ribosomal S6 kinase-mediated prorenin-converting enzyme in ischemic and diabetic myocardium'.

Circulation 20061024

Blockade of angiotensin II receptors reduces the expression of receptors for advanced glycation end products in human endothelial cells.

Arteriosclerosis, thrombosis, and vascular biology 20061001

Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma.

Cardiovascular research 20061001

Angiotensin II type 1 receptor blockade attenuates in-stent restenosis by inhibiting inflammation and progenitor cells.

Hypertension (Dallas, Tex. : 1979) 20061001

The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage.

Journal of hypertension 20061001

Verification of cefmetazole and cefpodoxime proxetil contamination to other pharmaceuticals by liquid chromatography-tandem mass spectrometry.

Chemical & pharmaceutical bulletin 20061001

Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers.

Clinical and experimental hypertension (New York, N.Y. : 1993) 20061001

The effect of angiotensin II receptor blockade on an end-stage renal failure model of type 2 diabetes.

Journal of cardiovascular pharmacology 20061001

[Efficacy and safety of olmesartan medoxomil versus losartan potassium in Chinese patients with mild to moderate essential hypertension].

Zhonghua xin xue guan bing za zhi 20061001

Imaging the renin-angiotensin system: an important target of anti-hypertensive therapy.

Advanced drug delivery reviews 20060915

Additive effects of combined blockade of AT1 receptor and HMG-CoA reductase on left ventricular remodeling in infarcted rats.

American journal of physiology. Heart and circulatory physiology 20060901

Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists.

Vascular pharmacology 20060901

Angiotensin II-dependent Src and Smad1 signaling pathway is crucial for the development of diabetic nephropathy.

Laboratory investigation; a journal of technical methods and pathology 20060901

Olmesartan, migraine, and blood pressure.

Headache 20060901

Angiotensin II type 1 receptor blocker attenuates exacerbated left ventricular remodeling and failure in diabetes-associated myocardial infarction.

Journal of cardiovascular pharmacology 20060901

Olmesartan reducing incidence of endstage renal disease in diabetic nephropathy trial (ORIENT): rationale and study design.

Hypertension research : official journal of the Japanese Society of Hypertension 20060901

A review of telmisartan in the treatment of hypertension: blood pressure control in the early morning hours.

Vascular health and risk management 20060901

Critical appraisal of C-reactive protein throughout the spectrum of cardiovascular disease.

Vascular health and risk management 20060901

Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor.

The Journal of biological chemistry 20060714

Blood pressure reduction with olmesartan in mild-to-moderate essential hypertension: a planned interim analysis of an open label sub-study in German patients.

Current medical research and opinion 20060701

Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate.

Blood pressure monitoring 20060601

Severity of hyperlipidemia does not affect antiatherosclerotic effect of an angiotensin II receptor antagonist in apolipoprotein E-deficient mice.

Journal of cardiovascular pharmacology 20060601

Two cases of fatal amlodipine overdose.

Journal of analytical toxicology 20060601

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20060601

[A novel synthesis of olmesartan medoxomil and examination of its related impurities].

Yao xue xue bao = Acta pharmaceutica Sinica 20060601

Megalin binds and internalizes angiotensin-(1-7).

American journal of physiology. Renal physiology 20060501

OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker.

Drug metabolism and disposition: the biological fate of chemicals 20060501

Pigment-epithelium-derived factor (PEDF) inhibits angiotensin-II-induced vascular endothelial growth factor (VEGF) expression in MOLT-3 T cells through anti-oxidative properties.

Microvascular research 20060501

Functional and bioenergetic consequences of AT1 antagonist olmesartan medoxomil in hearts with postinfarction LV remodeling.

Journal of cardiovascular pharmacology 20060501

Effects of angiotensin II type 1 receptor blockade on the systemic blood nitric oxide dynamics in Nomega-nitro-L-arginine methyl ester-treated rats.

Hypertension research : official journal of the Japanese Society of Hypertension 20060501

Pigment epithelium-derived factor (PEDF) blocks angiotensin II-induced T cell proliferation by suppressing autocrine production of interleukin-2.

Medicinal chemistry (Shariqah (United Arab Emirates)) 20060501

Role of p90 ribosomal S6 kinase-mediated prorenin-converting enzyme in ischemic and diabetic myocardium.

Circulation 20060411

Effects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertension.

Journal of human hypertension 20060401

Initial combination therapy with olmesartan/hydrochlorothiazide in moderate-to-severe hypertension.

Journal of human hypertension 20060401

Angiotensin II infusion decreases plasma adiponectin level via its type 1 receptor in rats: an implication for hypertension-related insulin resistance.

Metabolism: clinical and experimental 20060401

Effect of the angiotensin II receptor blocker olmesartan on the development of murine acute myocarditis caused by coxsackievirus B3.

Clinical science (London, England : 1979) 20060301

The importance of early antihypertensive efficacy: the role of angiotensin II receptor blocker therapy.

Journal of human hypertension 20060301

Targeting effective blood pressure control with angiotensin receptor blockers.

International journal of clinical practice 20060301

Prevention of migraine with olmesartan in patients with hypertension/prehypertension.

Headache 20060301

Augmentation of intrarenal angiotensin II levels in uninephrectomized aldosterone/salt-treated hypertensive rats; renoprotective effects of an ultrahigh dose of olmesartan.

Hypertension research : official journal of the Japanese Society of Hypertension 20060301

Effects of eprosartan on target organ protection.

Vascular health and risk management 20060301

Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.

Journal of hypertension 20060201

Opposing actions of angiotensin II type 1 and 2 receptors on plasma cholesterol levels in rats.

Journal of hypertension 20060101

Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b.

Theoretical biology & medical modelling 20060101

[Renoprotective and antihypertensive effect of combination therapy with a low protein diet, long-term exercise and angiotensin II receptor antagonist in rats with renal ablation].

Nihon Jinzo Gakkai shi 20060101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20060101

A review of the efficacy of fixed-dose combinations olmesartan medoxomil/hydrochlorothiazide and amlodipine besylate/benazepril in factorial design studies.

American journal of cardiovascular drugs : drugs, devices, and other interventions 20060101

Differential effects of olmesartan and ramipril on inflammatory response after myocardial infarction in rats.

Blood pressure 20060101

C-reactive protein (CRP)-lowering agents.

Cardiovascular drug reviews 20060101

Amlodipine versus angiotensin II receptor blocker; control of blood pressure evaluation trial in diabetics (ADVANCED-J).

BMC cardiovascular disorders 20060101

The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): rationale and baseline characteristics.

American journal of cardiovascular drugs : drugs, devices, and other interventions 20060101

Hydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controlled by monotherapy.

Advances in therapy 20060101

Pharmacokinetics of olmesartan medoxomil plus hydrochlorothiazide combination in healthy subjects.

Clinical drug investigation 20060101

Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals.

Clinical drug investigation 20060101

Relationship between the frequency of blood pressure self-measurement and blood pressure reduction with antihypertensive therapy : results of the OLMETEL (OLMEsartan TELemonitoring blood pressure) study.

Clinical drug investigation 20060101

Effect of olmesartan medoxomil on atherosclerosis: clinical implications of the emerging evidence.

American journal of cardiovascular drugs : drugs, devices, and other interventions 20060101

Olmesartan medoxomil: a clinical review.

Indian heart journal 20060101

Effects of olmesartan medoxomil as an angiotensin II-receptor blocker in chronic hypoxic rats.

European journal of pharmacology 20051228

Hydrolysis of angiotensin II receptor blocker prodrug olmesartan medoxomil by human serum albumin and identification of its catalytic active sites.

Drug metabolism and disposition: the biological fate of chemicals 20051201

Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering.

Journal of the American Society of Nephrology : JASN 20051201

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20051201

Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension.

Journal of hypertension 20051101

A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker.

Journal of cardiovascular pharmacology 20051101

Angiotensin receptor blockers ameliorate collagen-induced arthritis in mice: comment on the article by Sagawa et al.

Arthritis and rheumatism 20051101

Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor.

Clinical pharmacology and therapeutics 20051101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20051101

[Primary cardiorenal prevention in patients with type-2 diabetes. The Roadmap study].

Presse medicale (Paris, France : 1983) 20051022

Chronic administration of olmesartan attenuates the exaggerated pressor response to glutamate in the rostral ventrolateral medulla of SHR.

Brain research 20051005

Chronic nitroglycerine administration reduces endothelial nitric oxide production in rabbit mesenteric resistance artery.

British journal of pharmacology 20051001

The regressive effect of an angiotensin II receptor blocker on formed fatty streaks in monkeys fed a high-cholesterol diet.

Journal of hypertension 20051001

Effect of combined treatment with an angiotensin II receptor antagonist and an HMG-CoA reductase inhibitor on atherosclerosis in genetically hyperlipidemic rabbits.

Journal of cardiovascular pharmacology 20051001

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20051001

Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells.

Circulation research 20050902

Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats.

American journal of physiology. Heart and circulatory physiology 20050901

AT1 receptor-mediated enhancement of collecting duct renin in angiotensin II-dependent hypertensive rats.

American journal of physiology. Renal physiology 20050901

Olmesartan, a novel AT1 antagonist, suppresses cytotoxic myocardial injury in autoimmune heart failure.

American journal of physiology. Heart and circulatory physiology 20050901

Essential roles of angiotensin II in vascular endothelial growth factor expression in sleep apnea syndrome.

Respiratory medicine 20050901

Reaching for aggressive blood pressure goals: role of angiotensin receptor blockade in combination therapy.

The American journal of managed care 20050901

Olmesartan ameliorates insulin sensitivity by modulating tumor necrosis factor-alpha and cyclic AMP in skeletal muscle.

Hypertension research : official journal of the Japanese Society of Hypertension 20050901

Self-association properties of 4-[1-hydroxy-1-methylethyl]-2-propyl-1-[4-[2-[tetrazole-5-yl]phenyl]phenyl] methylimidazole-5-carboxylic acid monohydrate (CS-088), an antiglaucoma ophthalmic agent.

International journal of pharmaceutics 20050811

Mechanism of permeability-enhancing effect of EDTA and boric acid on the corneal penetration of 4-[1-hydroxy-1-methylethyl]-2-propyl-1-[4-[2-[tetrazole-5-yl]phenyl]phenyl] methylimidazole-5-carboxylic acid monohydrate (CS-088).

International journal of pharmaceutics 20050811

Angiotensin II infusion increases hepatic triglyceride production via its type 2 receptor in rats.

Journal of hypertension 20050801

Enhanced intrarenal angiotensinogen contributes to early renal injury in spontaneously hypertensive rats.

Journal of the American Society of Nephrology : JASN 20050701

Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice.

Journal of hypertension 20050701

Role of blood pressure reduction in prevention of cardiac and vascular hypertrophy.

American journal of hypertension 20050701

Renin-angiotensin system modulates oxidative stress-induced endothelial cell apoptosis in rats.

Hypertension (Dallas, Tex. : 1979) 20050601

Angiotensin receptor blockers suppress antigen-specific T cell responses and ameliorate collagen-induced arthritis in mice.

Arthritis and rheumatism 20050601

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20050601

In vivo imaging of oxidative stress in the kidney of diabetic mice and its normalization by angiotensin II type 1 receptor blocker.

Biochemical and biophysical research communications 20050506

Effect of azelnidipine on angiotensin II-mediated growth-promoting signaling in vascular smooth muscle cells.

Molecular pharmacology 20050501

Biliary excretion of olmesartan, an anigotensin II receptor antagonist, in the rat.

Journal of gastroenterology and hepatology 20050501

Effect of CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure in glaucomatous monkey eyes.

Experimental eye research 20050501

Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers effectively and directly potentiate superoxide scavenging by polymorphonuclear leukocytes from patients with type 2 diabetes mellitus.

The American journal of the medical sciences 20050501

Pharmacological and pharmacokinetic study of olmesartan medoxomil in animal diabetic retinopathy models.

European journal of pharmacology 20050411

Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes.

Journal of the American Society of Nephrology : JASN 20050401

Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress.

Hypertension (Dallas, Tex. : 1979) 20050401

Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists.

Hypertension (Dallas, Tex. : 1979) 20050401

Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats.

Journal of the American Society of Nephrology : JASN 20050301

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20050301

Synergistic effect of EDTA and boric acid on corneal penetration of CS-088.

International journal of pharmaceutics 20050216

Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals.

American journal of hypertension 20050201

Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.

American journal of cardiovascular drugs : drugs, devices, and other interventions 20050101

Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers.

International journal of clinical pharmacology research 20050101

['High dosage monotherapy'].

Krankenpflege Journal 20050101

Olmesartan medoxomil, a newly developed angiotensin II type 1 receptor antagonist, protects against renal damage in advanced glycation end product (age)-injected rats.

Drugs under experimental and clinical research 20050101

Comparative efficacy of valsartan and olmesartan in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoring.

Advances in therapy 20050101

Angiotensin type 1 receptor blockage improves ischemic injury following transient focal cerebral ischemia.

Neuroscience 20050101

Effects of olmesartan and enalapril at low or high doses on cardiac, renal and vascular interstitial matrix in spontaneously hypertensive rats.

Blood pressure 20050101

Reactive oxygen species-mediated signaling pathways in angiotensin II-induced MCP-1 expression of proximal tubular cells.

Antioxidants & redox signaling 20050101

[Olmesartan after experimental myocardial infarct compared with ramipril: organ protective effect].

Krankenpflege Journal 20050101

Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients.

Clinical pharmacokinetics 20050101

The angiotensin-II (AT-II) receptor blocker olmesartan reduces renal damage in animal models of hypertension and diabetes.

Proceedings of the Western Pharmacology Society 20050101

[Olmesartan: antihypertensive therapy].

Krankenpflege Journal 20050101

Efficacy and Safety of Olmesartan in the Treatment of Mild-to-Moderate Essential Hypertension in Chinese Patients.

Clinical drug investigation 20050101

Unequal effects of renin-angiotensin system inhibitors in acute cardiac dysfunction induced by isoproterenol.

American journal of physiology. Heart and circulatory physiology 20041201

Telemonitoring of blood pressure self measurement in the OLMETEL study.

Blood pressure monitoring 20041201

The renal protective effects of angiotensin II receptor blockers in type 2 diabetes mellitus.

The Annals of pharmacotherapy 20041001

Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity.

Journal of hypertension 20041001

[Pharmacological profiles and clinical effects of olmesartan medoxomil, a novel angiotensin II receptor blocker].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20041001

Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies.

Journal of clinical hypertension (Greenwich, Conn.) 20041001

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20041001

[The drug of the month: Olmesartan medoxomil].

Revue medicale de Liege 20041001

Additive beneficial effects of the combination of a calcium channel blocker and an angiotensin blocker on a hypertensive rat-heart failure model.

Hypertension research : official journal of the Japanese Society of Hypertension 20041001

Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress.

Arteriosclerosis, thrombosis, and vascular biology 20040901

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20040901

Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation.

Circulation 20040831

Prolonged endoplasmic reticulum stress in hypertrophic and failing heart after aortic constriction: possible contribution of endoplasmic reticulum stress to cardiac myocyte apoptosis.

Circulation 20040810

Angiotensin II type 1 receptor blocker ameliorates overproduction and accumulation of triglyceride in the liver of Zucker fatty rats.

American journal of physiology. Endocrinology and metabolism 20040801

AT-1 receptor blockade prevents proteinuria, renal failure, hyperlipidemia, and glomerulosclerosis in the Imai rat.

Kidney international 20040801

Salutary effects of attenuation of angiotensin II on coronary perivascular fibrosis associated with insulin resistance and obesity.

Journal of molecular and cellular cardiology 20040801

Effects of olmesartan medoxomil on systolic blood pressure and pulse pressure in the management of hypertension.

American journal of hypertension 20040801

Olmesartan improves endothelin-induced hypertension and oxidative stress in rats.

Hypertension research : official journal of the Japanese Society of Hypertension 20040701

Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling.

Circulation research 20040514

Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors.

Hypertension (Dallas, Tex. : 1979) 20040501

Angiotensin type-1 receptor blockade increases ACE 2 expression in the heart.

Hypertension (Dallas, Tex. : 1979) 20040501

AT1 receptor mediated augmentation of intrarenal angiotensinogen in angiotensin II-dependent hypertension.

Hypertension (Dallas, Tex. : 1979) 20040501

Evidence of tubular hypoxia in the early phase in the remnant kidney model.

Journal of the American Society of Nephrology : JASN 20040501

[Carbonyl stress inhibitor towards new therapeutic interventions in diabetic nephropathy].

Nihon rinsho. Japanese journal of clinical medicine 20040501

Use of an olmesartan medoxomil-based treatment algorithm for hypertension control.

Journal of clinical hypertension (Greenwich, Conn.) 20040401

Beneficial effects of olmesartan, a novel angiotensin II receptor type 1 antagonist, upon acute autoimmune myocarditis.

Molecular and cellular biochemistry 20040401

Olmesartan medoxomil, an angiotensin II receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructose-fed rats.

Hypertension research : official journal of the Japanese Society of Hypertension 20040401

Monocyte chemoattractant protein-1 is an essential inflammatory mediator in angiotensin II-induced progression of established atherosclerosis in hypercholesterolemic mice.

Arteriosclerosis, thrombosis, and vascular biology 20040301

AT1 receptor blocker added to ACE inhibitor provides benefits at advanced stage of hypertensive diastolic heart failure.

Hypertension (Dallas, Tex. : 1979) 20040301

Acute vascular effects of the angiotensin II receptor antagonist olmesartan in normal subjects: relation to the renin-aldosterone system.

American journal of hypertension 20040301

Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide.

American journal of hypertension 20040301

Angiotensin receptor blockers and diuretics as combination therapy: clinical implications.

American journal of hypertension 20040301

Antihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide.

Expert opinion on pharmacotherapy 20040301

[Development of combined drugs (ARB and diuretics)].

Nihon rinsho. Japanese journal of clinical medicine 20040301

Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan.

Hypertension (Dallas, Tex. : 1979) 20040201

Olmesartan inhibits the expression of monocyte chemoattractant protein-1 and tumor necrosis factor-alpha and improves vascular remodeling after vascular injury in mouse.

Chinese journal of traumatology = Zhonghua chuang shang za zhi 20040201

Protein kinase C and extracellular signal regulated kinase are involved in cardiac hypertrophy of rats with progressive renal injury.

European journal of clinical investigation 20040201

Renal effects of 26-week administration of olmesartan medoxomil/hydrochlorothiazide in rats.

The Journal of toxicological sciences 20040201

Angiotensin II induces endothelin-1 gene expression via extracellular signal-regulated kinase pathway in rat aortic smooth muscle cells.

Cardiovascular research 20040101

[Clinical profiles of new angiotensin II receptor blockers: telmisartan, olmesartan medoxomil, and irbesartan].

Nihon rinsho. Japanese journal of clinical medicine 20040101

Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.

Drugs 20040101

Antagonizing the angiotensin II subtype 1 receptor: a focus on olmesartan medoxomil.

Clinical therapeutics 20040101

Can the pharmacokinetic characteristics of olmesartan medoxomil contribute to the improvement of blood pressure control?

Clinical therapeutics 20040101

Clinical efficacy and tolerability of olmesartan.

Clinical therapeutics 20040101

Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials.

Clinical therapeutics 20040101

The role of olmesartan medoxomil in the management of hypertension.

Drugs 20040101

Clinical and experimental aspects of olmesartan medoxomil, a new angiotensin II receptor antagonist.

Cardiovascular drug reviews 20040101

[From the beginning -- a strong-acting and well tolerable antihypertensive agent. The recipe against constant change].

MMW Fortschritte der Medizin 20031204

[Dosage equivalents of AT1-receptor antagonists available in Germany].

Deutsche medizinische Wochenschrift (1946) 20031031

[Fast and strong lowering of pressure. The newest sartan has passed the practice test].

MMW Fortschritte der Medizin 20031030

Estrogen or the AT1 antagonist olmesartan reverses the development of profound hypertension in the congenic mRen2. Lewis rat.

Hypertension (Dallas, Tex. : 1979) 20031001

Olmesartan, an AT1-selective antihypertensive agent.

Drugs of today (Barcelona, Spain : 1998) 20031001

[Fast to the blood pressure goal. Lengthy dose adjustments harm compliance].

MMW Fortschritte der Medizin 20030925

[Not just blood pressure counts. How well are hypertensive patients controlled?].

MMW Fortschritte der Medizin 20030918

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20030901

A newly developed angiotensin II type 1 receptor antagonist, CS866, promotes regression of cardiac hypertrophy by reducing integrin beta1 expression.

Hypertension research : official journal of the Japanese Society of Hypertension 20030901

The preferential inhibitory effect of olmesartan, a new angiotensin II type 1 antagonist, on sympathetic nerve terminals in isolated canine splenic artery.

Journal of pharmacological sciences 20030801

Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury.

Hypertension (Dallas, Tex. : 1979) 20030701

An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells.

British journal of pharmacology 20030701

Cardiology patient page. Angiotensin receptor blockers.

Circulation 20030624

[Fast-acting sartan. High blood pressure therapy without long waiting time].

MMW Fortschritte der Medizin 20030612

Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension.

Journal of human hypertension 20030601

Should increasing the dose or adding an AT1 receptor blocker follow a relatively low dose of ACE inhibitor initiated in acute myocardial infarction?

Cardiovascular research 20030601

Angiotensin II-induced modulation of endothelium-dependent relaxation in rabbit mesenteric resistance arteries.

The Journal of physiology 20030501

Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model.

Journal of the American Society of Nephrology : JASN 20030501

Clinical efficacy of olmesartan medoxomil.

Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20030501

Effects of olmesartan, an angiotensin II receptor blocker, on mechanically-modulated genes in cardiac myocytes.

Cardiovascular drugs and therapy 20030501

Olmesartan medoxomil: an angiotensin II-receptor blocker.

Clinical therapeutics 20030401

Chronic angiotensin II inhibition increases levels of calcitonin gene-related peptide mRNA of the dorsal root ganglia in spontaneously hypertensive rats.

Hypertension research : official journal of the Japanese Society of Hypertension 20030301

Anti-atherosclerotic effects by AT1 receptor blockade.

Journal of hypertension 20030201

Mechanisms of angiotensin II type 1 receptor blocker for anti-atherosclerotic effect in monkeys fed a high-cholesterol diet.

Journal of hypertension 20030201

New drugs 2003, part I.

Nursing 20030201

[New AT1 receptor antagonist. Rapid and effective blood pressure decrease].

MMW Fortschritte der Medizin 20030130

Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: olmesartan medoxomil compared with losartan, valsartan, and irbesartan.

PharmacoEconomics 20030101

Olmesartan medoxomil: the seventh angiotensin receptor antagonist.

The Annals of pharmacotherapy 20030101

Beneficial effects of combination of ACE inhibitor and angiotensin II type 1 receptor blocker on cardiac remodeling in rat myocardial infarction.

Cardiovascular research 20030101

Effects of temocapril and olmesartan on myocardial sympathetic nervous activity and fatty acid metabolism in rats with chronic beta-adrenergic stimulation.

Journal of cardiovascular pharmacology 20030101

CS-088, an angiotensin type 1 receptor antagonist, ameliorated the impaired blood flow in the optic nerve head of rabbits.

Ophthalmic research 20030101

Effects of antihypertensive drugs on peritoneal vessels in hypertensive dogs with mild renal insufficiency.

Advances in peritoneal dialysis. Conference on Peritoneal Dialysis 20030101

Role of adhesion molecules in the progression of peritoneal sclerosis.

Advances in peritoneal dialysis. Conference on Peritoneal Dialysis 20030101

Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension.

Clinical drug investigation 20030101

[Changed guidelines of the German High Blood Pressure League. AT(1) blocker in the first league now].

MMW Fortschritte der Medizin 20021031

[New AT1-blocker is approved; 'me too' or progress?].

MMW Fortschritte der Medizin 20021003

Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms.

Journal of the American Society of Nephrology : JASN 20021001

Chronic angiotensin-converting enzyme inhibition and angiotensin II antagonism in rats with chronic renal failure.

Journal of cardiovascular pharmacology 20021001

Effect of estrogen and AT1 receptor blocker on neointima formation.

Hypertension (Dallas, Tex. : 1979) 20021001

An angiotensin-converting enzyme inhibitor, not an angiotensin II type-1 receptor blocker, prevents beta-aminopropionitrile monofumarate-induced aortic dissection in rats.

Journal of vascular surgery 20021001

Strategies to meet lower blood pressure goals with a new standard in angiotensin II receptor blockade.

American journal of hypertension 20021001

Beyond blood pressure: the endothelium and atherosclerosis progression.

American journal of hypertension 20021001

The role of angiotensin II receptor blockers in preventing the progression of renal disease in patients with type 2 diabetes.

American journal of hypertension 20021001

CS-886, a new angiotensin II type 1 receptor antagonist, ameliorates glomerular anionic site loss and prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats.

Molecular medicine (Cambridge, Mass.) 20021001

Guanylyl cyclase-A inhibits angiotensin II type 1A receptor-mediated cardiac remodeling, an endogenous protective mechanism in the heart.

Circulation 20020924

Inhibition of renin-angiotensin system ameliorates endothelial dysfunction associated with aging in rats.

Arteriosclerosis, thrombosis, and vascular biology 20020901

Olmesartan (benicar) for hypertension.

The Medical letter on drugs and therapeutics 20020805

Beneficial effects of combined blockade of ACE and AT1 receptor on intimal hyperplasia in balloon-injured rat artery.

Arteriosclerosis, thrombosis, and vascular biology 20020801

Lower the pressure with a new antihypertensive.

The Nurse practitioner 20020801

Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers synergistically increase coronary blood flow in canine ischemic myocardium: role of bradykinin.

Journal of the American College of Cardiology 20020703

Differential regulation of elevated renal angiotensin II in chronic renal ischemia.

Hypertension (Dallas, Tex. : 1979) 20020701

Trophic effect of olmesartan, a novel AT1R antagonist, on spinal motor neurons in vitro and in vivo.

Neurological research 20020701

Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy.

Hypertension research : official journal of the Japanese Society of Hypertension 20020701

[Therapy of hypertension. A new rapidly effective AT1 blocker].

MMW Fortschritte der Medizin 20020620

[Therapy of hypertension. AT1 blockers soon to be the first choice?].

MMW Fortschritte der Medizin 20020509

Anti-atherosclerotic efficacy of olmesartan.

Journal of human hypertension 20020501

The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview.

Journal of human hypertension 20020501

Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs.

Journal of human hypertension 20020501

Comparative antihypertensive efficacy of olmesartan: comparison with other angiotensin II receptor antagonists.

Journal of human hypertension 20020501

Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes.

Hypertension research : official journal of the Japanese Society of Hypertension 20020301

Inhibitory effect of a novel angiotensin II type 1 receptor antagonist RNH-6270 on growth of vascular smooth muscle cells from spontaneously hypertensive rats: different anti-proliferative effect to angiotensin-converting enzyme inhibitor.

Journal of cardiovascular pharmacology 20020201

The renin-angiotensin and adrenergic nervous system in cardiac hypertrophy in fructose-fed rats.

American journal of hypertension 20020101

Are there meaningful differences in blood pressure control with current antihypertensive agents?

American journal of hypertension 20020101

Use of angiotensin II receptor blockers in animal models of atherosclerosis.

American journal of hypertension 20020101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20020101

Olmesartan medoxomil.

Drugs 20020101

Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements.

Journal of clinical hypertension (Greenwich, Conn.) 20020101

A review of olmesartan medoxomil monotherapy: antihypertensive efficacy similar to that of other angiotensin II receptor blocker/hydrochlorothiazide combinations?

Congestive heart failure (Greenwich, Conn.) 20020101

Long-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patients.

Hypertension research : official journal of the Japanese Society of Hypertension 20011101

[Effects of CS-866, an angiotensin II receptor antagonist, in 5/6 nephrectomized spontaneously hypertensive rats].

Nihon Jinzo Gakkai shi 20011001

Differential subcellular actions of ACE inhibitors and AT(1) receptor antagonists on cardiac remodeling induced by chronic inhibition of NO synthesis in rats.

Hypertension (Dallas, Tex. : 1979) 20010901

The effect of topical CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure and aqueous humor dynamics in rabbits.

Current eye research 20010801

The effect of angiotensin II on uveoscleral outflow in rabbits.

Current eye research 20010801

Relevance of clinical pharmacological models for the evaluation of therapeutic dose range of an AT1-receptor antagonist.

Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20010601

The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction.

Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20010601

In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist.

Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20010601

Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil.

Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20010601

Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist.

Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20010601

Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives.

Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20010601

Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects.

Journal of clinical pharmacology 20010501

New pharmacologic aspects of CS-866, the newest angiotensin II receptor antagonist.

The American journal of cardiology 20010419

Clinical studies of CS-866, the newest angiotensin II receptor antagonist.

The American journal of cardiology 20010419

Pressure, platelets, and plaque: the central role of angiotensin II in cardiovascular pathology. Concluding comment.

The American journal of cardiology 20010419

Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation.

Circulation research 20010119

Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.

Journal of clinical hypertension (Greenwich, Conn.) 20010101

Angiotensin II type-1 receptor antagonist, CS-866, reduces blood pressure without affecting glucose/insulin metabolism in cholesterol-fed rabbits.

British journal of biomedical science 20010101

144689-63-4 | 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester

Product Description

Properties

Literature

Related Products

Featured Products